

CURRICULUM VITAE

Peter Anthony Campochiaro, M.D.

ADDRESS

Johns Hopkins Hospital School of Medicine
The Wilmer Eye Institute
719 Maumenee, 600 N. Wolfe Street
Baltimore, MD 21287-9277

DATE AND PLACE OF BIRTH

September 23, 1952
Cohoes, New York

CITIZENSHIP

United States

MARITAL STATUS

Married, Elizabeth Anne Campochiaro

EDUCATION

9/70 - 5/74:

University of Notre Dame, South Bend, IND; B.S., Phi Beta
Kappa, magna cum laude

9/74 - 5/78:

Johns Hopkins University School of Medicine, Baltimore, MD;
M.D. AOA

ACADEMIC HONORS

1978:

Sandoz Research Award

1978:

Henry Strong Denison Research Award

1978:

AOA, Johns Hopkins University

1995:

Rosenthal Award from the Macula Society

1995:

Alcon Research Institute Recognition Award

1996

Lew L. Wasserman Merit Award from Research to Prevent
Blindness

1998:

The George S. and Dolores Doré Eccles Endowed
Professorship

1999:

Steinbach Foundation Merit Award

2003:

Macula Vision Research Foundation Merit Award

2006:

Research to Prevent Blindness Senior Scientist Award

2013:

Senior Research Achievement Award from Macula Society

2014:

Retinal Research Foundation and Retina Society

Achievement Award for Retinal Research

2017:

National Academy of Inventors

EMPLOYMENT

- 7/78 - 6/79: Intern in Internal Medicine
Johns Hopkins Hospital, Baltimore, MD
- 7/79 - 6/82: Resident in Ophthalmology University of Virginia,
Charlottesville, VA
- 7/82 - 6/83: Fight for Sight Research Fellowship in Retinal
Neurochemistry, Dr. Joseph Coyle sponsor Department of
Neuroscience, Johns Hopkins Medical School, Baltimore,
MD
- 7/82 - 1/83: Fellow in Neuro-ophthalmology
Dr. Neil Miller, sponsor
Wilmer Institute
Johns Hopkins Hospital, Baltimore, MD
- 1/83 - 6/84: Fellow in Vitreoretinal Surgery and Retinal Cell Biology
Drs. Ronald Michels and Bert Glaser, sponsors
Wilmer Institute,
Johns Hopkins Hospital, Baltimore, MD
- 7/84 - 6/86: Assistant Professor of Ophthalmology
University of Virginia School of Medicine
Charlottesville, VA
- 7/86 - 7/90: Associate Professor of Ophthalmology
University of Virginia School of Medicine
Charlottesville, VA
- 7/90 - 7/91: Professor of Ophthalmology
University of Virginia School of Medicine
Charlottesville, VA
- 7/91 – 8/98: Professor of Ophthalmology and Neuroscience
Co-Director of Vitreoretinal Surgery
The Wilmer Institute
The Johns Hopkins University School of Medicine
Baltimore, MD
- 9/98 – 1/05 George S. and Dolores Doré Eccles
Professor of Ophthalmology and Neuroscience
Director, Vitreoretinal Surgery
The Wilmer Institute
The Johns Hopkins University School of Medicine

Baltimore, MD

1/05 – present

George S. and Dolores Doré Eccles
Professor of Ophthalmology and Neuroscience
The Wilmer Institute
The Johns Hopkins University School of Medicine
Baltimore, MD

PROFESSIONAL SOCIETIES

American Academy of Ophthalmology
American Association for the Advancement of Science
American Diabetes Association
American Medical Association
American Society for Cell Biology
American Society of Retina Specialists
Association for Research in Vision and Ophthalmology
International Society for Eye Research
Macula Society
Retina Society
Wilmer Residents Association

GRANTS

Active

2019-2023

Integrin-binding Peptide for Ocular Neovascularization and
Macular Edema: Molecular Mechanism of Action
Sponsor: NIH/NEI
Grant number: R01 EY028996
Co-principal investigator

2015-present

Biomaterial Inhibitor of HIF-1 for Prolonged Anti-
Angiogenesis in Eye
Sponsor: NIH/NIBIB
Grant number: R01 EB10612
Co-Principal Investigator

2016-present

Sustained Suprachoroidal Delivery of Therapeutic Peptides
for Ocular Diseases
Sponsor: NIH/NEI
Grant number: R21 EY026148
Co-Principal Investigator

2015-present

Development of a Mimetic Multimodal Peptide for
Treatment of Macular Edema

Sponsor: NIH/NEI
Grant number: R43 EY015903
Sub-Principal Investigator

Past Grants

1985-1986

“The Role of the Retinal Pigment Epithelium in the Pathogenesis of Diabetic Retinopathy”

Sponsor: NIH, DRTC Pilot feasibility

Grant Number: 5P60-AM22125-08

Principal Investigator

1985-2016

“Pathogenic Mechanisms in Proliferative Vitreoretinopathy”

Since 1994, “Functions of PDGFs and FGFs in the Retina and RPE”

Since 2007, “Oxidative Damage and Cone Cell Death in RP”

Sponsor: NIH, NEI

Grant Number: R01 EY05951

Principal Investigator

1986-1988

“Progressive Ultrastructural Damage and Induced

Expression of Aldose Reductase in Diabetic Retinopathy”

Sponsor: American Diabetes Association

Grant Number: None

Principal Investigator

1991-2001

“Mediators of Blood-Retinal Barrier Breakdown”

Sponsor: NIH, NEI

Grant Number: R01 EY10017

Co-Investigator

1992-1995

“Inhibition of Intraocular Proliferative Disorders with Retinoids”

Sponsor: Allergan, Inc.

Grant Number: None

Principal Investigator

1993-2012

“Identification and Characterization of RPE-Specific Genes”

Part of FFB Center since 1999

Sponsor: Foundation Fighting Blindness

Grant Number: None

Co-Investigator

1997-2006 “Inhibition of Ocular Neovascularization”
Sponsor: Novartis Ophthalmics, Inc.
Grant Number: None
Principal Investigator

1998-2012 “Effect of Neurotrophic Factors on Retinal Degenerations:
Use of an Inducible Transgenic System”
Part of FFB Center since 1999
Sponsor: Foundation Fighting Blindness
Grant Number: None
Principal Investigator

1998-2000 “Development of a Model of Choroidal
Neovascularization”
Sponsor: American Health Assistance Foundation
Grant Number: None
Principal Investigator

1999-2012 “FFB Center for the Study of Retinal Degenerations and
AMD at the Wilmer Eye Institute”
Sponsor: Foundation Fighting Blindness
Grant Number: None
Principal Investigator

2000-2004 “Molecular Biology of AAV”
Sponsor: NIH, NEI; subcontract from University of
Florida
Grant Number: R01 EY13101
Subcontract Number: UF 00005
Co-Investigator

2000-2004 “Expression of Anti-Angiogenic Agents with AAV
Vectors”
Sponsor: Juvenile Diabetes Research Foundation
Grant Number: None
Subcontract from University of Florida Center Grant

2000-2003 “Identification of Inhibitors of Ocular Neovascularization”
Sponsor: R.W. Johnson
Grant Number: None
Principal Investigator

2000-2011 “Effects in the Eye of Purported Inhibitors of
Angiogenesis”
Sponsor: Alcon

	Grant Number: None Principal Investigator
2000-2005	“Gene Therapy for Ocular Neovascularization” K08 Clinician-Scientist Award for Dr. Peter Gehlbach Sponsor: NIH, NEI Mentor
2001-2006	“Analysis of VMD2: a Model for RPE Gene Regulation” Sponsor: NIH, NEI Grant Number: RO1EY013357 Co-investigator
2001-2006	“Effects of Supplemental Inspired Oxygen in Hypoxia-mediated Retinal and Choroidal Diseases” K23 Clinician-Scientist Award for Dr. Quan Nguyen Sponsor NIH, NEI Mentor
2001-2008	By invitation from Foundation Fighting Blindness FFB Medical Therapy Assessment Center Principal Investigator
2009-2012	Sustained delivery of anti-angiogenic peptides for ocular neovascularization Sponsor: Thome Foundation Principal Investigator
2009-2014	“Vasohibin Gene Therapy for Diabetic Retinopathy” Sponsor: Juvenile Diabetes Research Foundation Principal Investigator
2011-2016	“Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity” Sponsor: NIH Grant Number: R01 EY020609 Subcontract from John Cooke, Stanford University
2012-2016	Biodegradable serpin-peptide-carrying nanoparticles for Wet AMD Sponsor: NIH/NEI Grant Number: R21 EY022986 Co-investigator
2012-2017	The Role of Alpha 4 Integrin in Ocular Neovascularization

Sponsor: Elan Pharmaceuticals, Inc.
Principal Investigator

2015-2018

Suppression of Retinal Neovascularization By Synthetic Peptides
Sponsor: Allegro Ophthalmics, LLC
Principal Investigator

2016-2018

Novel anti-angiogenic peptide
Sponsor: Ocugenix
Principal Investigator

CLINICAL TRIALS

“A multicenter, randomized, double-masked placebo-controlled parallel group dose finding phase II study of PKC412 (50, 100, 150 mg/day) in patients with diabetic macular edema”

Sponsor: Novartis Ophthalmics, Inc.
Principal Investigator

“Sandostatin LAR for moderate or severe nonproliferative diabetic retinopathy”

Sponsor: Novartis Pharmaceuticals
Co-investigator

“Intraocular Sustained Release of Dexamethasone for Macular Edema” (Posurdex)

Sponsor: Allergan
Co-investigator

“Supplemental Oxygen for Hypoxia-Mediated Retinal Diseases”

Sponsor: NIH, NEI
Grant Number: K23 EY13552
Mentor for K23

“Exploratory Study of the Safety, Tolerability and Biological Activity of VEGF Trap in Patients with Neovascular Age-related Macular Degeneration”

Sponsor: Regeneron
Co-investigator

“An Open Label, Long-term, Safety and Tolerability Study of VEGF Trap in Patients with Neovascular Age-related Macular Degeneration”

Sponsor: Regeneron
Co-investigator

“Evaluation of Retina of Subjects without Diabetic Mellitus and Subjects with Diabetes Mellitus without Retinopathy using Optical Coherence Tomography”

Sponsor: NA

Co-investigator

“An Open Label, Pilot (Phase I/II), Dose-escalation Safety and Tolerability Study of Combretastatin A4 Phosphate in Patients with Neovascular Age-related Macular Degeneration”

Sponsor: Foundation Fighting Blindness

Co-investigator

“An Open Label, Phase I, Single Administration, Dose-escalation Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)”

Sponsor: GenVec

Grant Number: None

Principal Investigator

“A Phase III Multi-center, Randomized, Double Masked, Sham Injection Controlled Study of the Efficacy and Safety of rhuFab V2 (ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-related Macular Degeneration”

Sponsor: Genentech

Co-investigator

“A Pilot, Open-label Study of the Safety, Tolerability and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Diabetes Mellitus (READ1 Trial)”

Sponsor: JDRF

Grant Number: None

Senior Investigator

“**Ranibizumab for Edema of the Macula in Diabetes; the READ2 Trial**”

A multicenter trial to investigate the effect of ranibizumab in patients with diabetic macular edema”

Sponsor: JDRF

Grant number: None

Senior investigator, Executive Committee

“Multi-center, masked, Randomized, Sham-controlled Trial Assessing the Safety and Efficiency of Dexamethasone Posterior Segment Drug Delivery System in Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion” (Posurdex)

Sponsor: Allergan

Co-investigator

“A Randomized, Open-label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Due to Retinal Vein Occlusions”

Physician-initiated IND to study the effect of Ranibizumab in patients with macular edema due to central or branch retinal vein occlusions.

Sponsor: Genentech

Principal Investigator

“A Phase III, Multicenter, Randomized, Sham-controlled Study of the Efficacy and Safety of Ranibizumab Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion; the CRUISE Study”

Sponsor Genentech

Principal Investigator at JHU site and lead investigator

“A Phase III, Multicenter, Randomized, Sham-controlled Study of the Efficacy and Safety of Ranibizumab Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion: the BRAVO Study”

Sponsor Genentech

Principal Investigator at JHU site and lead investigator

“A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts in Patients with Diabetic Macular Edema”

Sponsor: Alimera

Principal Investigator at JHU site

A Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/day Fluocinolone Acetonide/Medidur™ in patients with Exudative Age-

Related Macular Degeneration Who Have Received
Lucentis™: the MAP Study”

Sponsor: Alimera
Principal Investigator

“An open label pharmacokinetic and efficacy study of 0.5
µg/day and 0.2 µg/day Fluocinolone Acetonide Intravitreal
Inserts in Subjects with Diabetic Macular Edema”

Sponsor: Alimera
Principal Investigator

“Phase 2 study of the safety and bioactivity of topical
ocular mecamylamine for the treatment of diabetic macular
edema”

Sponsor: CoMentis
Principal Investigator

“The VIBRANT trial: aflibercept for branch retinal vein
occlusion

Sponsor: Regeneron
Principal Investigator

“A Phase I, Open-Label, Multi-Center, Dose Escalating,
Safety and Tolerability Study of a Single Intra-Vitreous
Injection of AAV2-sFLT01 in Patients with Neovascular
Age-Related Macular Degeneration”

Sponsor: Genzyme Corporation
Principal Investigator

Subretinal Injection of Retinostat in Patients with
Neovascular Age-Related Macular Degeneration
Sponsor” Oxford BioMedica (UK) Ltd.

Principal Investigator

Long Term Follow-up Study to Evaluate the Safety of
RetinoStat in Patients with Age-Related Macular
Degeneration

Sponsor” Oxford BioMedica (UK) Ltd.
Principal Investigator

GX29185: A Phase III, Multicenter, Randomized, Double-
Masked, Sham-Controlled Study to Assess the Efficacy and
Safety of Lampalizumab Administered Intravitreally to
Patients with Geographic Atrophy Secondary to Age-
Related Macular Degeneration

Sponsor: Genentech

Principal Investigator at JHU site

GX30191: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study.

Genentech

Principal Investigator at JHU site

Phase 2a Open-Label Study to Assess the Efficacy and Safety of Subcutaneous 15 mg AKB-9778 Administered Twice Daily for 84 Days in Subjects with Retinal Vein Occlusion involving AKB-9778

Sponsor: Aerpio Therapeutics

Principal Investigator

R2176-3-AMD-1417 - A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration

Sponsor: Regeneron Pharmaceuticals, Inc.

Principal Investigator at JHU site

Phase 4 Safety Study of IOP Signals in Patients Treated with ILUVEIN (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg

Sponsor: Alimera Sciences, Inc.

Role: Principal Investigator

A Phase 1/2 Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects with Advanced Neovascular Age-related Macular Degeneration.

Sponsor: RXI Pharmaceuticals Corp

Principal Investigator

A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration.

Genentech

Principal Investigator at JHU site

BP29647 A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
Roche Translational & Clinical Research Center
Principal Investigator at JHU site

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration
Allergan
Principal Investigator at JHU site

A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
Regeneron Pharmaceuticals, Inc.
Principal Investigator at JHU site

A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration
The major goal of this project is to test the effect of blocking VEGF and angiopoietin 2 versus VEGF alone in patients with neovascular age-related macular degeneration.
Regeneron Pharmaceuticals, Inc.
Principal Investigator at JHU site

A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients w/Diabetic Macular Edema
The major goal of this project is to test the effect of blocking VEGF and angiopoietin 2 versus VEGF alone in patients with diabetic macular edema.
Regeneron Pharmaceuticals, Inc.
Principal Investigator at JHU site

BP30099 A Multiple-Center, Multiple-Dose Randomized, Active Comparator-Controlled, Double-Masked, Parallel

Group, 28 Week Study to Investigate the Safety,
Tolerability, Pharmacokinetics, and Efficacy of
RO6867461 Administered Intravitreally in Patients with
Diabetic Macular Edema
Roche Translational & Clinical Research Center
Principal Investigator at JHU site

INVITED LECTURES

- 10/85: Duke University Eye Center, Durham, NC
"Pathogenic Mechanisms in Proliferative Vitreoretinopathy"
- 3/86: 5th Vail Vitreoretinal Seminar
Sponsored by Duke University in Vail, CO
"Cellular Migration in the Pathogenesis of Proliferative
Vitreoretinopathy"
"The Blood-Retinal Barrier and Retinal Reattachment"
- 9/86: International Symposium on Ocular Circulation and
Neovascularization, Jerusalem, Israel
"Localization of Angiogenesis Markers to Inner and Outer
Retina"
- 4/87: Duke Advanced Vitreous Surgery Course
Duke University, Durham NC
"The Cell Biology of Proliferative Vitreoretinopathy"
"Strategies in Designing Therapies in Proliferative
Vitreoretinopathy"
"Practical Approach to Endophthalmitis"
- 10/87: Diabetes Research Center
University of Virginia School of Medicine
"The Role of Retinal Pigment Epithelium in Diabetic
Retinopathy"
- 11/87: Department of Anatomy & Cell Biology
University of Virginia School of Medicine
"The Cell Biology of Proliferative Vitreoretinopathy"
- 3/88: Visiting Professor
Department of Ophthalmology
University of Alabama at Birmingham
- 5/88: Visiting Professor

Department of Ophthalmology
University of Tennessee School of Medicine, Memphis

- 9/88: International Symposium on Proliferative Vitreoretinopathy
Cologne, West Germany
"The Role of Breakdown of the Blood-retinal Barrier in
Cell Injection Models of Proliferative Vitreoretinopathy"
- 11/88: Visiting Professor
Department of Ophthalmology
Medical College of Virginia, Richmond, VA
- 3/89: 6th Vail Vitreoretinal Seminar
Sponsored by Duke University in Vail, Co
"Clinical Risk Factors for Proliferative Vitreoretinopathy"
"Inhibition of Growth Factor Induced Effects in Retinal
Pigment Epithelial Cells"
- 5/89: American Academy of Ophthalmology Focus Course on
Posterior Segment Laser
Durham, NC
"Treatment of Choroidal Neovascularization"
- 10/89: International Symposium on Diabetes
Sponsored by the Diabetes Research Center
University of Virginia, Charlottesville, VA
"The Pathogenesis of Diabetic Retinopathy"
- 11/89: The American Academy of Ophthalmology
New Orleans, LA
Symposium on Ocular Wound Healing
"Antimetabolites and Other Agents in the Treatment of
Proliferative Vitreoretinopathy"
- 8/90: Ninth International Congress of Eye Research
Helsinki, Finland
Symposium on RPE: Receptors and Growth Factors
"Human Retinal Pigment Epithelial Cells Possess Cholinergic and
Vasopressin Receptors Coupled to Calcium Mobilization"
- 9/90: Alcon Lecturer
The Emory Eye Center
Robert W. Woodruff Health Sciences Center
"Mechanisms Involved in Breakdown of the Blood-Retinal
Barrier in Diabetic Retinopathy"

"Mechanisms Involved in Breakdown of the Blood-Retinal Barrier in Ocular Inflammatory Disease"
"Spontaneous Involution of Subfoveal Neovascularization"

- 4/91: Visiting Professor
Departments of Anatomy and Cell Biology and Ophthalmology
Bowman Gray School of Medicine
Winston-Salem, NC
- 9/92: Tenth International Congress of Eye Research
Stresa, Italy
Symposium on Cytodifferentiation of RPE
"Laminin and bFGF Promote Differentiation of RPE *in Vitro*"
- 11/92: The American Academy of Ophthalmology
Dallas, TX
"Angiogenic Factors in Choroidal Neovascularization"
- 1/93: The Japanese Retina Society
Fukuoka, Japan
"Treatment of Proliferative Vitreoretinopathy"
"Localization and Mechanisms of Breakdown of the Blood-Retinal Barrier in Retinal Diseases"
- 3/94: Guest Lecturer and Visiting Professor
Department of Ophthalmology
Casey Eye Institute
University of Oregon and Oregon Academy of Ophthalmology
- 3/94: Department of Ophthalmology
Tufts University
Frontiers in Vision Research Seminar Series
"Trophic Interactions Between Photoreceptors and Retinal Pigmented Epithelium"
- 1/95 The 18th Congress of the Japanese Society of Ophthalmic Surgery
"Growth Factors in the Retina: Pathophysiology and Therapeutic Implications"
- 3/95 Department of Ophthalmology
University of Alabama School of Medicine
Distinguished Lecture Series
"Trophic Interactions Between Photoreceptors and RPE"
- 4/95: Department of Neuroscience

- Cornell University
"Trophic Interactions Between Photoreceptors and Retinal Pigmented Epithelium"
- 8/95 The Second Great Basin Visual Science Symposium
University of Utah Health Sciences Center
"The Retinal Pigmented Epithelium and Retinal Wound Repair"
- 1/96 St. Louis Ophthalmological Society
"Management of Proliferative Diabetic Retinopathy"
"Trophic Interactions Between the Retina & the RPE"
- 10/96 Visiting Professor Lecture Series
Wills Eye Hospital
"Progress in Development of Pharmacologic Treatment of Ocular Neovascularization"
- 5/97 Visiting Professor
Goldschleger Institute - Bnai Zion Medical Center
Stein Award Dedication
"The Pathogenesis of Ocular Neovascularization; Insights From Genetically Engineered Mice With Overexpression of Growth Factors in the Retina"
- 9/97 Visiting Professor
Kansai Medical University
5th International Symposium on Ocular Circulation & Neovascularization
- 7/98 XIII International Congress of Eye Research
Paris, France
"A Novel Secreted Frizzled-Related Protein that is Differentially Expressed in the Retinal Pigmented Epithelium"
- 9/98 Guest Lecturer
German Academy of Ophthalmology
East Berlin, Germany
"Ocular Neovascularization"
- 6/00 European Union Symposium on the Retinal Pigmented Epithelium
Sintra, Portugal
"The Role of the RPE in Choroidal Neovascularization"
- 5/01 Harkness Eye Institute

- Columbia University School of Medicine
Visiting Professor
- 10/01 University of Louisville
Louisville Ophthalmological Society
Visiting Professor
- 4/02 University of Florida
Symposium on Age-related Macular Degeneration
“Drug and Gene Therapies for CNV”
- 12/04 University of California San Francisco
2004 Procter Lecture
“Pathogenesis & Treatment of Diabetic Macular Edema”
- 10/06 University of Illinois, Chicago
Key note address at “Frontiers in Vision Research”
New Treatments for Ocular Neovascularization”
- 3/07 The Richard Chenoweth Lecture
Casey Eye Institute
University of Oregon Health Sciences University
“New Treatments for Ocular Neovascularization and
Macular Edema”
- 4/07 The Brazilian Retina and Vitreous Society Meeting
Urberlandia, Brazil
Invited speaker
“VEGF antagonists for Diabetic Macular Edema”
“Ocular Gene Therapy”
- 6/07 The Peking University International Ophthalmic Forum
Beijing, China
Invited Speaker
“New Treatments for Ocular Neovascularization and
Macular Edema”
“Ocular Gene Therapy”
“Oxidative Damage and Cone Cell Death in Retinitis
Pigmentosa”
- 11/07 Bauch and Lomb Visiting Professor at the University of
Rochester Department of Ophthalmology
“Molecular Pathogenesis of Ocular Neovascularization and
Macular Edema”
“VEGF Antagonists for Retinal Vascular Diseases”

- 12/07 Irving H. Leopold Lecture
Allergan, Newport Beach, CA
“Ocular Neovascularization and Macular Edema”
- 3/08 Visiting Professor
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia
“Ocular Neovascularization, A Valuable Model System”
- 3/08 Visiting Professor
King Khalid Eye Specialist Hospital
Riyadh, Saudi Arabia
“New Treatments for Choroidal Neovascularization and Diabetic Macular Edema”
- 3/08 Invited Speaker at Workshop entitled “Regulation of Tumor Angiogenesis and Lymphangiogenesis” sponsored by US-Japan Cooperative Cancer Research Program.
Kyoto, Japan
“Molecular Pathogenesis of Ocular Neovascularization; Similarities and Differences With Tumor Angiogenesis”
- 6/08 Visiting Professor
Institute of Ophthalmology
University College
London, England
“Pathogenesis of Cone Cell Death in Retinitis Pigmentosa”
- 6/08 Visiting Professor
Moorfields Eye Institute
London, England
“New Treatments for Diabetic Macular Edema and Retinal Vein Occlusions”
- 9/08 Invited Keynote Speaker
XIIIth International Symposium on Retinal Degenerations
Emeishan, Sichuan, China
“Oxidative Damage and Cone Cell Death in Retinitis Pigmentosa”
- 3/09 Visiting Professor
New Jersey Medical School
Newark, NJ
“Mechanisms Involved in the Pathogenesis of Ocular Neovascularization”
“New Treatments for Diabetic Macular Edema”

- 6/09 Robert S. Jampel, MD, PhD Endowed Lectureship
Kresge Eye Institute
Wayne State University
Detroit, MI
“New Treatments for Ocular Neovascularization and Macular Edema”
- 3/10 Kimura Endowed Lectureship
University of California at San Francisco
San Francisco, CA
“New Treatments for Ocular Neovascularization and Macular Edema”
- 7/10 Faculty for Intensive Training Course for Ophthalmology Residents of the University of Bologna, Italy
Lecce, Italy
“Mechanism of Cone Cell Death in Retinitis Pigmentosa”
“Mechanisms and Potential New Treatments for Ocular Neovascularization”
- 11/10 Ruth Kroon Memorial Lecture
University of Nebraska
Omaha, Nebraska
“Ocular Neovascularization: Mechanisms and Prospects for New Treatments”
- 11/10 The National Academy of Science and Medicine of Argentina
National University of Cordoba
Cordoba, Argentina
“Ocular Neovascularization: Mechanisms and Prospects for New Treatments”
The Association for Research in Vision and Ophthalmology of Argentina
Cordoba, Argentina
Keynote Lecture
“Mechanism of Cone Cell Death in Retinitis Pigmentosa”
Asociacion de Jovenes Oftalmologos de Cordoba
“Is VEGF Blockade Toxic to the Retina”
- 6/11 Federal Drug Administration
“Gene Transfer for Ocular Neovascularization”
- 9/11 Visiting Professor
University of Michigan

- “Pathogenesis of Ocular Neovascularization”
 “New Treatments for Diabetic Macular Edema and Retinal Vein Occlusions”
- 12/12 Anniversary of Founding of Department of Ophthalmology
 of University of Vienna, Austria
 Invited lecturer
 “Pathogenesis and Treatment of Diabetic Retinopathy”
- 1/14 Visiting Professor
 Nagoya University, Nagoya, Japan
 “Mechanisms of Cone Cell Death in Retinitis Pigmentosa”
- 1/14 Retinal Diseases Symposium
 Osaka, Japan
 “Treatment of Macular Edema Due to Retinal Vein Occlusions”
- 5/14 Knapp Symposium of American Ophthalmological Society
 Invited lecturer
 “Pharmacologic Delivery with Gene Therapy”
- 5/15 Genetic & Regenerative Medicine of Eye Disease Series
 Schepens Eye Research Institute
 “Mechanism of Cone Cell Death in Retinitis Pigmentosa”
- 8/16 Wihuri Research Institute Symposium
 Helsinki, Finland
 Targeting Vascular Leak, Inflammation and Atherosclerosis
 “Tie2 in Diabetic Retinopathy”
- 10/16 Invited Speaker
 Allergan Seminar Series
 Irvine, CA
 “Targeting Tie2 in Ocular Neovascularization and Macular Edema”
- 9/17 Keynote Lecture
 Humphries Symposium
 University of Virginia
 Charlottesville, VA
 “Recent Advances in the Management of Macular Edema”
- 4/18 2018 TransAmerican Lecture
 Resident’s Day

University of California at San Francisco
“New Treatments for Retinal and Choroidal Vascular
Diseases”

6/18 Keynote Speaker
Hadassah Ophthalmology Centennial Anniversary
Symposium
Jerusalem, Israel
“New Approaches for Treatment of Retinal and Choroidal
Vascular Diseases”

6/18 Invited Speaker
International Society of Vascular Biology
Helsinki, Finland
“Tie2 in Retinal and Choroidal Vascular Diseases”

PUBLICATIONS IN REFEREED JOURNALS

1. Coyle JT and **Campochiaro PA** (1976). Ontogenesis of dopaminergic-cholinergic interactions in the rat striatum: a neurochemical study. *J Neurochem* 27:673-678.
2. Coyle JT, Schwarcz R, Bennett JP and **Campochiaro PA** (1977). Clinical, neuropathologic and pharmacologic aspects of Huntington's disease; correlated with a new animal model. *Progress in Neuropsychopharmacol* 1:13-30.
3. **Campochiaro PA**, Schwarcz R and Coyle JT (1977). GABA receptor binding in rat striatum: localization and effects of denervation. *Brain Res* 136 (3):501-511.
4. **Campochiaro PA** and Coyle JT (1978). Ontogenetic development of kainate neurotoxicity: correlates with glutamatergic innervation. *Proc Natl Acad Sci USA* 75:2025-2029.
5. **Campochiaro PA**, Ferkany JW and Coyle JT (1984). The dissociation of evoked release of [³H]-GABA and of endogenous GABA from chick retina *in vitro*. *Exp Eye Res* 39, 299-305.
6. **Campochiaro PA**, Jerdan JA and Glaser BM (1984). Serum contains chemoattractants for human retinal pigment epithelial cells. *Arch Ophthalmol* 102:1830-1833.
7. **Campochiaro PA**, Kaden IH, Vidaurri-Leal J and Glaser BM (1985). Cryotherapy enhances intravitreal dispersion of viable retinal pigment epithelial cells. *Arch Ophthalmol* 103:434-436.
8. **Campochiaro PA** and Glaser BM (1985). Platelet-derived growth factor is chemotactic for retinal pigment epithelial cells. *Arch Ophthalmol* 103:576-579.
9. **Campochiaro PA**, Ferkany JW and Coyle JT (1985). Excitatory amino acid analogs evoke release of putative transmitters from isolated chick retina *in vitro*. *Vision Res* 25:1375-1386.

10. **Campochiario PA**, Jerdan JA, Glaser BM, Cardin A and Michels RG (1985). Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol 103:1403-1405.
11. Jaccoma EH, Conway BP and **Campochiario PA (1985)**. Cryotherapy causes extensive breakdown of the blood-retinal barrier. A comparison with argon laser photocoagulation. Arch Ophthalmol 103:1728-1730.
12. Glaser BM, **Campochiario PA**, Davis JL and Sato M (1985). Retinal pigment epithelial cells release an inhibitor of neovascularization. Arch Ophthalmol 103:1870-1875.
13. **Campochiario PA** and Glaser BM (1985). Endothelial cells release a chemoattractant for retinal pigment epithelial cells *in vitro*. Arch Ophthalmol 103:1876-1880.
14. **Campochiario PA** and Glaser BM (1986). Mechanisms involved in retinal pigment epithelial cell chemotaxis. Arch Ophthalmol 104:277-280.
15. Conway BP and **Campochiario PA** (1986). Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin. Arch Ophthalmol 104:367-371.
16. Haller Yeo J, Sadeghi J, **Campochiario PA**, Green WR and Glaser BM (1986). Intravitreal Fibronectin and platelet-derived growth factor: a new model for traction retinal detachment. Arch Ophthalmol 104:417-421.
17. Bryan JA III and **Campochiario PA** (1986). A retinal pigment epithelial cell-derived growth factor. Arch Ophthalmol 104:422-425.
18. **Campochiario PA** and Glaser BM (1986). A retina-derived stimulator(s) of retinal pigment epithelial cell and astrocyte proliferation. Exp Eye Res 43:449-457.
19. **Campochiario PA**, Jerdan JA and Glaser BM (1986). The extracellular matrix of human retinal pigment epithelial cells *in vivo* and its synthesis *in vitro*. Invest Ophthalmol Vis Sci 27:1615-1621.
20. **Campochiario PA**, Bryan JA III, Conway BP and Jaccoma EH (1986). Intravitreal chemotactic and mitogenic activity. Implication of blood-retinal barrier breakdown. Arch Ophthalmol 104:1685-1687.
21. Hackett SF, Friedman Z and **Campochiario PA** (1986). Cyclic 3',5'- adenosine monophosphate modulates retinal pigment epithelial cell migration *in vitro*. Arch Ophthalmol 104:1688-1692.
22. Friedman Z, Hackett SF and **Campochiario PA** (1987). Characterization of adenylate cyclase activity in human retinal pigment epithelial cells *in vitro*. Exp Eye Res 44:471-479.
23. Glaser BM, **Campochiario PA**, Davis JL Jr. and Jerdan, JA (1987). Retinal pigment epithelial cells

- release inhibitors of neovascularization. *Ophthalmology* 94:780-784.
24. Hackett SF, Friedman Z and **Campochiaro PA** (1987). Cyclic 3',5'- adenosine monophosphate modulates vascular endothelial cell migration *in vitro*. *Cell Biol Internat Rep* 11:279-287.
 25. Dircks C, Williams EH and **Campochiaro PA** (1987). High glucose concentrations inhibit protein synthesis in retinal pigment epithelium *in vitro*. *Exp Eye Res* 44:951-958.
 26. Stahl JH, Miller DB, Conway BP and **Campochiaro PA** (1987). Dexamethasone and indomethacin attenuate cryopexy-induced breakdown of the blood-retinal barrier. *Graefe's Arch Clin Exp Ophthalmol* 225:418-420.
 27. **Campochiaro PA**, Gaskin HC and Viores SA (1987). Retinal cryopexy stimulates traction retinal detachment formation in the presence of an ocular wound. *Arch Ophthalmol* 105:1567-1570.
 28. Wilson WG, **Campochiaro PA**, Conway BP, Carter BT, Sudduth KW, Atkin JF, Watson BA and Sparkes RS (1987). Deletion (13)(Q14.1 Q14.3) in two generations. Variability of ocular manifestations and definition of the phenotype. *Amer J Med Gen* 28:675-683.
 29. Hackett SF and **Campochiaro PA** (1988). Implication of protein carboxymethylation in retinal pigment epithelial cell chemotaxis. *Ophthalmic Res* 20:54-59.
 30. Friedman Z, Hackett SF and **Campochiaro PA** (1988). Human retinal pigment epithelial cells possess muscarinic receptors coupled to calcium mobilization. *Brain Res* 446:11-16.
 31. Viores SA, **Campochiaro PA**, May E and Blaydes SH (1988). Progressive ultrastructural damage and basement membrane thickening of the retinal pigment epithelium in spontaneously diabetic BB rats. *Exp Eye Res* 46:545-558.
 32. **Campochiaro PA** and Blaydes SH (1988). Photocoagulation does not ablate angiogenic markers in rabbit retina. *Arch Ophthalmol* 106:676-679.
 33. Sen HA, Robertson TJ, Conway BP and **Campochiaro PA** (1988). The role of breakdown of the blood-retinal barrier in cell injection models of proliferative vitreoretinopathy. *Arch Ophthalmol* 106:1291-1294.
 34. **Campochiaro PA** and Conway BP (1988). Hemangioma-like masses of the retina. *Arch Ophthalmol* 106:1409-1413.
 35. Viores SA, **Campochiaro PA**, Williams EH, May EE, Green WR and Sorenson RL (1988). Aldose reductase expression in human diabetic retina and retinal pigment epithelium. *Diabetes* 37:1658-1664.
 36. Cowley M, **Campochiaro PA**, Newman SA and Fogle JA (1988). Retinal vascular occlusion without retrobulbar or optic nerve sheath hemorrhage after retrobulbar injection of lidocaine. *Ophthalmic Surg* 19:859-861.

37. **Campochiaro PA** (1988). Retinal thinning and regression of neovascularization. *Arch Ophthalmol* 106:1646-1647.
38. Conway BP, Tabatabay CA, **Campochiaro PA**, D'Amico DJ and Kenyon KR (1989). Gentamicin toxicity in the primate retina. *Arch Ophthalmol* 107:107-112.
39. Vinores SA, Gadegbeku C, **Campochiaro PA** and Green WR (1989). Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. *Am J Pathol* 134:231-235.
40. Hackett SF, Conway BP and **Campochiaro PA** (1989). Subretinal fluid stimulation of RPE migration and proliferation is dependent upon certain features of the detachment or its treatment. *Arch Ophthalmol* 107:391-394.
41. **Campochiaro PA** and Sen HA (1989). Adenosine and its agonists cause retinal vasodilation and hemorrhages: implications for ischemic retinopathy. *Arch Ophthalmol* 107:412-416.
42. Friedman Z, Hackett SF, Linden J and **Campochiaro PA** (1989). Human retinal pigment epithelial cells in culture possess A₂ adenosine receptors. *Brain Res* 492:29-35.
43. **Campochiaro PA**, Sugg R, Grotendorst G and Hjelmeland LM (1989). Retinal pigment epithelial cells produce PDGF-like proteins and secrete them into their media. *Exp Eye Res* 49:217-227.
44. **Campochiaro PA**, Mimuro J, Sugg R and Loskutoff DJ (1989). Retinal pigment epithelial cells produce a latent fibrinolytic inhibitor that is antigenically and biochemically related to type 1 plasminogen activator inhibitor produced by vascular endothelial cells. *Exp Eye Res* 49:195-203.
45. Sen HA and **Campochiaro PA** (1989). Intravitreal injection of adenosine or its agonists causes breakdown of the blood-retinal barrier. *Arch Ophthalmol* 107:1364-1367.
46. Vinores SA and **Campochiaro PA** (1989). Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition. *Exp Eye Res* 49:495.
47. Cowley M, Conway BP, **Campochiaro PA**, Kaiser D and Gaskin H (1989). Clinical risk factors for proliferative vitreoretinopathy. *Arch Ophthalmol* 107:1147-1151.
48. Vinores SA, **Campochiaro PA** and Conway BP (1990). Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. *Invest Ophthalmol Vis Sci* 31:14-28.
49. Leschey KH, Hackett SF, Singer JH and **Campochiaro PA** (1990). Growth factor responsiveness of human retinal pigment epithelial cells. *Invest Ophthalmol Vis Sci* 31:839-846.
50. **Campochiaro PA**, Morgan KM, Conway BP and Stathos J (1990). Spontaneous involution of subfoveal neovascularization. *Am J Ophthalmol* 109:668-675.

51. Viores SA, **Campochiaro PA**, Lee A, McGehee R, Gadegbeku C and Green WR (1990). Localization of blood-retinal barrier breakdown in human pathologic specimens by Immunohistochemical staining for albumin. *Lab Invest* 62:742-750.
52. Viores SA, McGehee R, Lee A, Gadegbeku C, **Campochiaro PA** (1990). Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats. *J Histochem Cytochem* 38:1341-1352.
53. Viores SA, **Campochiaro PA**, McGehee R, Orman W, Hackett SF and Hjelmeland LM (1990). Ultrastructural immunocytochemical changes in RPE, retinal glia, and fibroblasts in vitreous culture. *Invest Ophthalmol Vis Sci* 31:2529-2545.
54. **Campochiaro PA**, Hackett SF and Conway BP (1991). Retinoic acid promotes density-dependent growth arrest in retinal pigment epithelial cells. *Invest Ophthalmol Vis Sci* 32:65-72.
55. Leschey KH, Hines J, Singer JH, Hackett SF and **Campochiaro PA** (1991). Inhibition of growth factor effects in retinal pigment epithelial cells. *Invest Ophthalmol Vis Sci* 32:1770-1778.
56. Hackett SF, Singer JH, Leschey KH and **Campochiaro PA** (1991). Thrombin is a stimulator of retinal pigment epithelial cell proliferation. *Exp Eye Res* 53:95-100.
57. Sen HA and **Campochiaro PA** (1991). Stimulation of cyclic AMP accumulation causes breakdown of the blood-retinal barrier. *Invest Ophthalmol Vis Sci* 32:2006-2010.
58. Friedman Z, Delahunty TM, Linden J and **Campochiaro PA** (1991). Human retinal pigment epithelial cells possess V₁ vasopressin receptors. *Curr Eye Res* 10:811-816.
59. **Campochiaro, PA** and Conway BP (1991). Aminoglycoside toxicity: A survey of retinal specialists. *Arch Ophthalmol* 109:946-950.
60. **Campochiaro PA**, Van Niel E and Viores SA (1992). Immunocytochemical labeling of cells in cortical vitreous from patients with premacular hole lesions. *Arch Ophthalmol* 110:371-377.
61. Viores SA, Sen H and **Campochiaro PA** (1992). An adenosine agonist and prostaglandin E₁ cause breakdown of the blood-retinal barrier by opening tight junctions between vascular endothelial cells. *Invest Ophthalmol Vis Sci* 33:1870-1878.
62. **Campochiaro PA**, Gonzales-Fernandez F, Newman SA, Conway BP and Feldman PS (1992). Ciliary body adenoma in a 10 year-old girl who had rhabdomyosarcoma. *Arch Ophthalmol* 110:681-683.
63. Viores SA, Van Niel E, Kim HJ and **Campochiaro PA** (1992). Simultaneous expression of keratin and glial fibrillary acidic protein by the same cells in epiretinal membranes. *Invest Ophthalmol Vis Sci* 33:3361-3366.

64. **Campochiaro PA** and Green WR (1992). Toxicity of intravitreal ceftazidime in primate retina. *Arch Ophthalmol* 110:1625-1629.
65. Lim JI and **Campochiaro PA** (1992). Successful treatment of gram-negative endophthalmitis with intravitreal ceftazidime. *Arch Ophthalmol* 110:1686.
66. Vinos SA, Hermann MM, Hackett SF and **Campochiaro PA** (1993). A morphologic and immunohistochemical study of human retinal pigment epithelial cells, retinal glia, and fibroblasts grown on gelfoam matrix in an organ culture system: A comparison of structural and non-structural proteins and their application to cell type identification. *Graefes Arch Clin Exp Ophthalmol* 231:279-288.
67. Hackett SF and **Campochiaro PA** (1993). Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells. *Invest Ophthalmol Vis Sci* 34:2055-2061.
68. Vinos SA, Orman W, Hooks JJ, Detrick B and **Campochiaro PA** (1993). Ultrastructural localization of RPE-associated epitopes recognized by monoclonal antibodies in human RPE and their induction in human fibroblasts by vitreous. *Graefes Arch Clin Exp Ophthalmol* 231:395-401.
69. Hines J, Vinos SA and **Campochiaro PA** (1993). Evolution of morphologic changes after intravitreal injection of gentamicin. *Curr Eye Res* 12:521-529.
70. Gonzales-Fernandez F, Van Niel E, Edmonds C, Beaver H, Nickerson JM, Garcia-Fernandez JM, **Campochiaro PA** and Foster RG (1993). Differential expression of interphotoreceptor retinoid binding protein, opsin, cellular retinaldehyde-binding protein, and basic fibroblast growth factor. *Exp Eye Res* 56:411-427.
71. Vinos SA, Van Niel E, Swerdloff JC and **Campochiaro PA** (1993). Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. *Histochem J* 25:648-663.
72. Vinos SA, Van Niel E, Swerdloff JL and **Campochiaro PA** (1993). Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition. *Exp Eye Res* 57:723-735.
73. Glaser BM, Vidaurri-Leal J, Michels RG and **Campochiaro PA** (1993). Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. *Ophthalmology* 100:466-470.
74. **Campochiaro PA** and Hackett SF (1993). Corneal endothelial cell matrix promotes expression of differentiated features of retinal pigmented epithelial cells: implication of laminin and basic fibroblast growth factor as active components. *Exp Eye Res* 57:539-547.

75. **Campochiaro PA**, Lim J and the Aminoglycoside Study Group (1994). Aminoglycoside toxicity in the treatment of endophthalmitis. *Arch Ophthalmol* 112:48-53.
76. Lim JL, Enger C, Haller JA, **Campochiaro PA**, Meredith, TA, DeBustros S, Dunn JP and Jabs (1994). Improved visual results after surgical repair of cytomegalovirus-related retinal detachments. *Ophthalmology* 101:264-269.
77. **Campochiaro PA**, Hackett SF, Viores SA, Freund J, Csaky C, LaRochelle W, Henderer J, Johnson M, Rodriguez IR, Friedman Z, Derevjanik N and Dooner J (1994). Platelet derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. *J Cell Sci* 107:2459-2469.
78. Viores SA, Amin A, Derevjanik NL, Green WR and **Campochiaro PA** (1994). Immunohistochemical localization of blood-retinal barrier breakdown sites associated with post-surgical macular edema. *Histochem J* 26:655-665.
79. Fekrat S, de Juan E and **Campochiaro PA** (1995). The effect of oral 13-cis-retinoic acid on retinal redetachments after surgical repair in eyes with proliferative vitreoretinopathy. *Ophthalmology* 102:412-418.
80. Viores SA, Derevjanik NL, Mahlow J, Hackett SF, Haller JA, de Juan E, Frankfurter A and **Campochiaro PA** (1995). Class III β -tubulin in human retinal pigment epithelial cells in culture and in epiretinal membranes. *Exp Eye Res* 60:385-400.
81. Viores SA, Henderer JD, Mahlow J, Chiu C, Derevjanik NL, LaRochelle W, Csaky C and **Campochiaro PA** (1995). Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: immunolocalization to retinal pigmented epithelial cells. *Exp Eye Res* 607-619.
82. Viores SA, Kuchle M, Derevjanik NL, Henderer JD, Mahlow J, Green WR and **Campochiaro PA** (1995). Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. *Histol Histopath* 10:913-923.
83. Viores SA, Kuchle M, Mahlow J, Chiu C, Green WR and **Campochiaro PA** (1995). Blood-ocular barrier breakdown in eyes with ocular melanoma; a potential role for vascular endothelial growth factor. *Am J Pathol* 147:1289-1297.
84. **Campochiaro PA**, Chang M, Ohsato M, Viores SA, Nie Z, Hjelmeland L, Mansukhani A, Basilico C and Zack DJ (1996). Retinal degeneration in transgenic mice with photoreceptor-specific expression of a dominant-negative fibroblast growth factor receptor. *J Neurosci* 16:1679-1688.
85. Lazarus HS, Schoenfeld C-L, Fekrat S, Cohen S, Carol A, Hageman GS, Hackett S, Chen Y-S, Viores SA, **Campochiaro PA** (1996). Hyalocytes synthesize and secrete inhibitors of retinal pigment epithelial cell proliferation in vitro. *Arch Ophthalmol* 114:731-736.

86. Della NG, **Campochiaro PA** and Zack DJ (1996). Localization of TIMP-3 mRNA expression to retinal pigment epithelium. *Invest. Ophthalmol Vis Sci* 37:1921-1924.
87. Luna J, Tobe T, Mousa SA, Reilly TM and **Campochiaro PA** (1996). Antagonists of integrin B₃ inhibit retinal neovascularization in a murine model. *Lab Invest* 75:563-573.
88. Viores SA, Youssri AL, Luna JD, Chen Y-S, Bhargave S, Viores MA, Schoenfeld C-L, Peng B, Chan Ch-Ch, LaRochelle W, Green WR, **Campochiaro PA** (1997). Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. *Histol Histopathol* 12:99-109.
89. Viores SA, Viores MA, Chiu C, Woerner TM, **Campochiaro PA** (1997). Double-labeling for keratin and class III β (1)-tubulin within cultured retinal pigment epithelial cells: Comparison of chromogens to yield maximum resolution of two structural proteins within the same cell. *J Histochemol* 20:19-25.
90. Ozaki H, Hayashi H, Viores SA, Moromisato Y, **Campochiaro PA**, Oshima K (1997). Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. *Exp. Eye Res* 64:505-517.
91. Okamoto N, Tobe T, Hackett SF, Ozaki H, Viores M, LaRochelle W, Zack DJ, **Campochiaro PA** (1997). Transgenic mice with increased expression of VEGF in the retina: A new model of subretinal neovascularization. *Am J Pathol* 151:281-291.
92. Hackett SF, Schoenfeld C-L, Freund J, Gottsch JD, Bhargave S, **Campochiaro PA** (1997). Neurotrophic factors, cytokines and stress increase expression of basic fibroblast growth factor in retinal pigmented epithelial cells. *Exp Eye Res* 64:865-873.
93. Luna JD, Chan CC, Derevjani NL, Mahlow J, Chiu C, Peng B, Tobe T, **Campochiaro PA**, Viores SA (1997). Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor, and interleukin-1-mediated breakdown. *J Neurosci Res* 49:268-280.
94. Chang JT, Milligan S, Li Y, Chew CE, Wiggs J, Copeland NG, Jenkins NA, **Campochiaro PA**, Hyde DR, Zack DJ (1997). Mammalian homolog of drosophila retinal degeneration B rescues the mutant fly phenotype. *J Neurosci* 17:5881-5890.
95. Stefko ST, **Campochiaro PA**, Wang P, Li Y, Zhn D, Traboulsi EI (1997). Dominant inheritance of optic pits. *Am J Ophthalmol* 124:11-113.
96. Chen Y-S, Hackett SF, Schoenfeld C-L, Viores MA, Merges C, Luty GA, Viores SA, **Campochiaro PA** (1997). Localization of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. *Br J Ophthalmol* 81:919-926.
97. Zimmer-Galler IE, Santos A, Haller JA and **Campochiaro PA** (1997). Management of endophthalmitis in a silicone oil-filled eye. *Retina* 17:507-509.

98. Tobe T, Okamoto N, Viores M, Derevjanik N, Viores SA, Zack DJ and **Campochiaro PA** (1998). Evolution of neovascularization in mice with overexpression of VEGF in photoreceptors. *Invest Ophthalmol Vis Sci* 39:180-188.
99. Viores SA, Chan C-C, Viores MA, Matteson DM, Chen Y-S, Klein DA, Shi A, Ozaki H, **Campochiaro PA** (1998). Increased vascular endothelial growth factor (VEGF) and transforming growth factor- β (TGF- β) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. *J Neuroimmunol* 89:43-50.
100. Kennedy BN, Goldflam S, Chang MA, **Campochiaro PA**, Davis AA, Zack, DJ, Crabb JW (1998). Transcriptional regulation of cellular retinaldehyde-binding protein in the retinal pigment epithelium, a role for the photoreceptor consensus element. *J Biol Chem* 243:5591-5598.
101. Hackett SF, Friedman Z, Freund J, Schoenfeld C, Curtis R, DiStefano PS, and **Campochiaro PA** (1998). A splice variant of trkB and brain-derived neurotrophic factor are co-expressed in retinal pigmented epithelial cells and promote differentiated characteristics. *Brain Res* 789:201-212.
102. Swanson DA, Chang JT, **Campochiaro PA**, Zack DJ, Valle D (1998). Mammalian orthologs of the neuron-specific *C. elegans* UNC-119 gene are preferentially expressed in retinal photoreceptor cells. *Invest Ophthalmol Vis Sci* 39:2085-2094.
103. Ozaki H, Okamoto N, Ortega S, Chang M, Ozaki K, Sadda S, Viores MA, Derevjanik N, Zack DJ, Basilico C, **Campochiaro PA** (1998). Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. *Am J Pathol* 153:757-765.
104. Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL, Viores SA, Basilico C, **Campochiaro PA** (1998). Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. *Am J Pathol* 153:1641-1646.
105. Perez-Mediavilla LA, Chew C, **Campochiaro PA**, Nickells RW, Notario V, Zack DJ and Becerra SP (1998). Sequence and expression analysis of bovine pigment epithelium-derived factor. *Biochimica et Biophysica Acta* 1398:203-214.
106. Ozaki H, Aimee YY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, **Campochiaro PA** (1999). Hypoxia inducible factor-1 α is increased in ischemic retina: temporal and spatial correlation with VEGF expression. *Invest Ophthalmol Vis Sci* 40:182-189.
107. **Campochiaro PA**, Soloway P, Ryan SJ, Miller JW (1999). The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. *Molecular Vis* 5:34-38.
108. Yamada H, Yamada, E, Hackett SF, Ozaki H, Okamoto N, **Campochiaro PA** (1999). Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina. *J Cell Physiol* 179:149-156.

109. Chang JT, Ensumi N, Moore K, Li Y, Zhang S, Chew C, Goodman B, Rattner , Moody S, Stetten G, **Campochiaro PA**, Zack DJ (1999). Cloning and characterization of a secreted frizzled-related protein that is expressed by the retinal pigment epithelium. *Hum Mol Genet* 8:575-583.
110. Mousa SA, Lorelli W, **Campochiaro PA** (1999). Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells: potential implications in ocular neovascularization. *J Cell Biochem* 74:135-143.
111. Satta SR, **Campochiaro PA**, de Juan Jr. E, Haller JA, Green WR (1999). Histopathological features of vitreous removed at macular hole surgery. *Arch Ophthalmol* 117:478-484.
112. Seo MS, Kwak NH, Ozaki H, Yamada H, Okamoto N, Yamada E, Fabbro D, Hofmann F, Wood JM, **Campochiaro PA** (1999). Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. *Am J Pathol* 154:1743-1753.
113. Viores SA, Derevjanik NL, Ozaki H, Okamoto N, **Campochiaro PA** (1999). Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. *Doc Ophthalmol* 97:217-228.
114. Viores SA, Derevjanik NL, Viores MA, Okamoto N, **Campochiaro PA** (2000). Sensitivity of different vascular beds in the eye to neovascularization and blood-retinal barrier breakdown in VEGF transgenic mice. *Adv Exp Med Biol* 476: 129-138.
115. Mathura JR, Jafari N, Chang JT, Hackett SF, Wahlin KJ, Della NG, Okamoto N, Zack DJ, **Campochiaro PA** (2000). Bone morphologic proteins-2 and -4 are negative growth regulators that are abundantly expressed in the retinal pigmented epithelium. *Invest Ophthalmol Vis Sci* 41:592-600.
116. Ozaki H, Seo M-S, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JF, **Campochiaro PA** (2000). Blockade of VEGF receptor signaling is sufficient to completely prevent retinal neovascularization. *Am J Pathol* 156:697-707.
117. Yamada H, Yamada E, Ando A, Seo M-S, Ensumi N, Okamoto N, Viores M, LaRochelle W, Zack DJ, **Campochiaro PA** (2000). Platelet-derived growth factor-A-induced retinal gliosis protects against ischemic retinopathy. *Am J Pathol* 156:477-487.
118. Viores SA, Seo MS, Okamoto N, Ash JD, Wawrousek EF, Xiao WH, Hudish T, Derevjanik NL, **Campochiaro PA** (2000). Experimental models of growth factor-mediated angiogenesis and blood-retinal barrier breakdown. *Gen Pharmacol* 35:233-239.
119. Wahlin KJ, **Campochiaro PA**, Zack DJ, Adler R (2000). Neurotrophic factors causes activation of intracellular signaling pathways in Müller cells and other cells of the inner retina, but not photoreceptors. *Invest Ophthalmol Vis Sci* 41:927-936.
120. Hackett SF, Ozaki H, Strauss RW, Wahlin K, Suri C, Maisonpierre P, Yancopoulos G,

- Campochiaro PA** (2000). Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. *J Cell Physiol* 184:275-284.
121. Yamada H, Yamada E, Kwak N, Ando A, Suzuki A, Esumi N, Zack DJ, **Campochiaro PA** (2000). Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. *J Cell Physiol* 185:135-142.
122. Kwak N, Okamoto N, Wood JM, **Campochiaro PA** (2000). VEGF is major stimulator in a model of choroidal neovascularization. *Invest Ophthalmol Vis Sci* 41: 3158-3164.
123. Seo M-S, Okamoto N, Viores MA, Viores SA, Hackett SF, Yamada H, Yamada E, Derevjanik NL, LaRochelle W, Zack DJ, **Campochiaro PA** (2000). Photoreceptor specific expression of platelet-derived growth factor-B results in traction retinal detachment. *Am J Pathol* 157: 995- 1005.
124. Loewenstein A, Humayun M, de Juan E, Haller JA, **Campochiaro PA** (2000). Perfluoroperhydrophenanthrene versus perfluoro-*n*-octane in vitreoretinal surgery. *Am J Ophthalmol* 107:1078–1082.
125. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, **Campochiaro P**, Wood J, O'Reilly T, Meyer T (2000). PKC412-a protein kinase inhibitor with a broad therapeutic potential. *Anti-Cancer Drug Design* 15:17-28.
126. Yamada E, Tobe T, Yamada H, Okamoto N, Zack DJ, Werb Z, Soloway PD, **Campochiaro PA** (2001). TIMP-1 promotes VEGF-induced neovascularization in the retina. *Histol Histopathol* 16:87-97.
127. Shimura M, Yuan Y, Chang JT, Zhang S, **Campochiaro PA**, Zack DJ, Hughes BA (2001). Expression and permeation properties of the K(+) channel K in 7.1 in the retinal pigment epithelium. *J Physiol* 531:329-346.
128. Mori K, Akira A, Gehlbach P, Nesbitt D, Takahaski K, Goldsteen D, Penn M, Chen T, Mori K, Melia M, Phipps S, Moffat D, Brazzell K, Liao G, Dixon KH, **Campochiaro PA** (2001). Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. *Am J Pathol* 159:313-320.
129. Mori K, Duh E, Gehlbach P, Akira A, Takahaski K, Pearlman J, Mori K, Yang HS, Zack DJ, ETTYREDDY D, BROUGH DE, WEI LL, **Campochiaro PA** (2001). Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. *J Cell Physiol* 188:253-263.
130. Yamada H, Yamada E, Ando A, Esumi N, Bora N, Saikia J, Sung C-H, Zack DJ, **Campochiaro PA** (2001). FGF2 decreases hyperoxia-induced photoreceptor cell death in mice. *Am J Pathol* 159:1113-1120.
131. Yan W, Jang GF, Haeseleer F, Esumi N, Chang J, Kerrigan M, Campochiaro M, **Campochiaro P**, Palczewski K, Zack DJ (2001). Cloning and characterization of a human

beta, beta-carotene-15, 15'-dioxygenase that is highly expressed in the retinal pigment epithelium. *Genomics* 72: 193-202.

132. Wahlin KJ, Adler R, Zack DJ, **Campochiaro PA** (2001). Neurotrophic signaling in normal and degenerating rodent retinas. *Exp Eye Res* 73:693-701.
133. Fekrat S, Elsing SH, Raja SC, **Campochiaro PA**, de Juan E Jr., Haller JA (2001). Eye pain after vitreoretinal surgery: a prospective study of 185 patients. *Retina* 21:627-632.
134. Rasmussen H, Chu KW, **Campochiaro PA**, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU (2001). Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). *Hum Gene Ther* 12:2029-2032.
135. **Campochiaro PA** (2002). Gene therapy for choroidal and retinal diseases. *Expert Opin Biol Ther* 2:537-544.
136. Ohno-Matsui K, Hirose A, Yamamoto S, Saikia J, Okamoto N, Gehlbach P, Duh EJ, Hackett S, Chang M, Bok D, Zack DJ, **Campochiaro PA** (2002). Inducible expression of VEGF in adult mice causes severe proliferative retinopathy and retinal detachment. *Am J Pathol* 160:711-719.
137. Mori K, Gehlbach P, Yamamoto S, Duh E, Zack DJ, Li Q, Berns KI, Raisler BJ, Hauswirth WW, **Campochiaro PA** (2002). AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. *Invest Ophthalmol Vis Sci* 43: 1994-2000.
138. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, Katai M, Yan L, Suzuma K, West K, Davarya S, Tong P, Gehlbach P, Pearlman J, Crabb JW, Aiello LP, **Campochiaro P**, Zack DJ (2002). Pigment epithelium-derived factor (PEDF) suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. *Invest Ophthalmol Vis Sci* 43:821-829.
139. Ando A, Yang A, Mori K, Yamada H, Yamada E, Takahashi K, Saikia J, Kim M, Melia M, Fishman M, Huang P, **Campochiaro PA** (2002). Nitric oxide is proangiogenic in the retina and choroid. *J Cell Physiol* 191:116-124.
140. Mori K, Gehlbach P, Ando A, Wahlin K, Gunther V, McVey D, Wei L, **Campochiaro PA** (2002). Intraocular adenoviral vector-mediated gene transfer is increased in proliferative retinopathies. *Invest Ophthalmol Vis Sci* 43:1610-1615.
141. Mori K, Gehlbach P, Ando A, Dyer G, Lipinsky E, Chaudhry AG, Hackett SF, **Campochiaro PA** (2002). Retina-specific expression of PDGF-B versus PDGF-A; vascular versus nonvascular proliferative retinopathy. *Invest Ophthalmol Vis Sci* 43: 2001-2006.

142. Mori K, Gehlbach P, Ando A, McVey D, Wei L, **Campochiaro PA** (2002). Regression of ocular neovascularization by increased expression of pigment epithelium-derived factor. *Invest Ophthalmol Vis Sci* 43 : 2428-2434.
143. Hackett SF, Wiegand S, Yancopoulos G, **Campochiaro PA** (2002). Angiopoietin-2 plays an important role in retinal angiogenesis. *J Cell Physiol* 192: 182-187.
144. Derevjani NL, Viores SA, Xiao W, Mori K, Turon T, Hudish T, Dong S, **Campochiaro PA** (2002). Quantitative assessment of the integrity of the blood-retinal barrier in mice. *Invest Ophthalmol Vis Sci* 43: 2462-2467.
145. Takahashi K, Luo T, Saishin Y, Saishin Y, Sung J, Hackett S, Brazzell RK, Kaleko M, **Campochiaro PA** (2002). Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. *Hum Gene Ther* 13: 1305-1316.
146. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson D, Suri C, **Campochiaro PA**, Wiegand S, Yancopoulos G (2002). Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. *Dev Cell* 3: 411-423.
147. Ando A, Yang A, Nambu H, **Campochiaro PA** (2002). Blockade of nitric oxide synthetase reduces choroidal neovascularization. *Mol Pharmacol* 62:539-544.
148. Polito A, Shah SM, Haller JA, Zimmer-Galler I, Zeimer R, **Campochiaro PA**, Vitale S (2002). Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. *Am J Ophthalmol* 134:240-251.
149. Sharma S, Chang JT, Della NG, **Campochiaro PA**, Zack DJ (2002). Identification of novel bovine RPE and retinal genes by subtractive hybridization. *Mol Vis* 8: 251-258.
150. Pianta MJ, Aleman TS, Cideciyan AV, Sunness JS, Li Y, Campochiaro BA, **Campochiaro PA**, Zack DJ, Stone EM, Jacobson SG (2003). In vivo micropathology of Best macular dystrophy with optical coherence tomography. *Exp Eye Res* 76:203-211.
151. Viores SA, Seo MS, Derevjani NL, Campochiaro PA (2003). Photoreceptor-specific overexpression of platelet-derived growth factor induces proliferation of endothelial cells, pericytes, and glial cells and aberrant vascular development: an ultrastructural and immunocytochemical study. *Brain Res Dev Brain Res* 140:169-183.
152. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Duh E, Yang HS, Cingolani C, Lai H, Wei L, **Campochiaro PA** (2003). Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. *Gene Ther* 10:637-646.

153. Takahashi K, Saishin Y, Saishin Y, Mori K, Ando A, Yamamoto S, Oshima Y, Nambu H, Melia M, Bingaman D, **Campochiaro PA** (2003). Topical nepafenac inhibits ocular neovascularization. *Invest Ophthalmol Vis Sci* 44:409-415.
154. Demetriades AM, Gottsch JD, Thomsen R, Azab A, Stark WJ, **Campochiaro PA**, de Juan E Jr., Haller JA (2003). Combined phacoemulsification, intraocular lens implantation, and vitrectomy for eyes with coexisting cataract and vitreoretinal pathology. *Am J Ophthalmol* 135:291-296
155. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ, Yang HS, Lai H, Kovesdi I, Wei L, **Campochiaro PA** (2003). Periocular gene transfer of *sFlt-1* suppresses ocular neovascularization and VEGF-induced breakdown of the blood-retinal barrier. *Hum Gene Ther* 14:129-141.
156. Saishin Y, Saishin Y, Takahashi K, Melia M, Vinoses SA, **Campochiaro PA** (2003). Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. *J Cell Physiol* 195:210-219.
157. Saishin Y, Saishin Y, Takahashi K, Lima-Silva R, Hylton D, Rudge JS, Wiegand SJ, **Campochiaro PA** (2003). VEGF-TRAP_{R1R2} suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. *J Cell Physiol* 195:241-248.
158. Fekrat S, Marsh MJ, Elsing SH, Raja SC, de Juan E Jr, **Campochiaro PA**, Haller JA (2003). Intraoperative ketorolac and eye pain after vitreoretinal surgery: a prospective, randomized, placebo-controlled study. *Retina* 23:8-13.
159. Saishin Y, Saishin Y, Takahashi K, Seo M-S, Melia M, **Campochiaro PA** (2003). The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. *Invest Ophthalmol Vis Sci* 44:3656-3662.
160. Okoye G, Zimmer J, Sung J, Gehlbach P, Deering T, Nambu H, Hackett S, Melia M, Esumi N, Zack DJ, **Campochiaro PA** (2003). Increased expression of BDNF preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. *J Neurosci* 23:4164-4172.
161. Nambu H, Nambu R, Melia M, **Campochiaro PA** (2003). Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. *Invest Ophthalmol Vis Sci* 44:3650-3655.
162. Takahashi K, Saishin Y, Saishin Y, Lima-Silva R, Oshima Y, Oshima S, Melia M, Paszkiet B, Zerby D, Kadan MJ, Liao G, Kaleko M, Connelly S, Luo T, **Campochiaro PA** (2003). Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. *FASEB J* 17:896-898.

163. Chowers I, Gunatilaka TL, Farkas RH, Qian J, Hackam AS, Duh E, Kageyama M, Wang C, Vora A, **Campochiaro PA**, Zack DJ (2003). Identification of novel genes preferentially expressed in the retina using a custom human retina cDNA microarray. *Invest Ophthalmol Vis Sci* 44:3732-3741.
164. Chowers I, Liu D, Farkas RH, Gunatilaka TL, Hackam AS, Bernstein SL, **Campochiaro PA**, Parmigiani G, Zack DJ (2003). Gene expression variation in the adult human retina. *Hum Mol Genet* 12:2881-2893.
165. Saishin Y, Lima-Silva R, Saishin Y, Callahan K, Schoch C, Ahlheim M, Lai H, Kane F, Brazzell RK, Bodmer D, **Campochiaro PA** (2003). Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. *Invest Ophthalmol Vis Sci* 44:4989-4993.
166. Ida H, Tobe T, Nambu H, Matsumura M, Uyama M, **Campochiaro PA** (2003). RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGF. *Invest Ophthalmol Vis Sci* 44:5430-5437.
167. **Campochiaro PA**, Hackett SF (2003). Ocular neovascularization: a valuable model system. *Oncogene* 22:6537-6548.
168. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, **Campochiaro PA**, Semenza GL (2003). Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. *Circ Res* 93:1074-1081.
169. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, **Campochiaro PA** (2004). Supplemental oxygen improves diabetic macular edema: a pilot study. *Invest Ophthalmol Vis Sci* 45:617-624.
170. Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, Connelly S, Hackett SF, and **Campochiaro PA** (2004). Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. *J Cell Physiol* 199:412-417.
171. Oshima Y, Takahashi K, Oshima S, Saishin Y, Saishin, Y, Lima-Silva R, Liang X, Reddy PS, Ganesh S, Brann T, Liau G, Kaleko M, Connelly S, **Campochiaro PA** (2004). Intraocular gutless adenoviral vectored VEGF stimulates anterior segment but not retinal neovascularization. *J Cell Physiol* 199:399-411.
172. **Campochiaro PA**, and the C99-PKC412-003 Study Group (2004). Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. *Invest Ophthalmol Vis Sci* 45:922-931.

173. Nambu H, Nambu R, Oshima Y, Hackett SF, Wiegand S, Yancopoulos G, Zack DJ, **Campochiaro PA** (2004). Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. *Gene Ther* 11:865-873.
174. Esumi N, Oshima Y, Li Y, **Campochiaro PA**, Zack DJ (2004). Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation. *J Biol Chem* 279:19064-19073.
175. Duh EJ, Yang HS, Haller JA, De Juan E, Humayun MS, Gehlbach P, Melia M, Pieramici D, Harlan JB, **Campochiaro PA**, Zack DJ (2004). Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. *Am J Ophthalmol* 137:668-674.
176. Wahlin KJ, Lim L, Grice EA, **Campochiaro PA**, Zack DJ, Adler R (2004). A method for analysis of gene expression in isolated mouse photoreceptor and Muller cells. *Mol Vis* 10:366-375.
177. Chowers I, Kim Y, Farkas RH, Gunatilaka TL, Hackam AS, **Campochiaro PA**, Finnemann SC, Zack DJ (2004). Changes in retinal pigment epithelial gene expression induced by rod outer segment uptake. *Invest Ophthalmol Vis Sci* 45:2098-2106.
178. Hackam AS, Strom R, Liu D, Qian J, Wang C, Otteson D, Gunatilaka T, Farkas RH, Chowers I, Kageyama M, Leveillard T, Sahel JA, **Campochiaro PA**, Parmigiani G, Zack DJ (2004). Identification of gene expression changes associated with the progression of retinal degeneration in the rd1 mouse. *Invest Ophthalmol Vis Sci* 45:2929-2942.
179. **Campochiaro PA** (2004). Ocular neovascularization and excessive vascular permeability. *Expert Opin Biol Ther* 4:1395-1402.
180. Oshima Y, Oshima S, Nambu H, Kachi S, Hackett SF, Melia M, Kaleko M, Connelly S, Esumi N, Zack DJ, **Campochiaro PA** (2004). Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. *J Cell Physiol* 201:393-400.
181. Shen J, Samul R, Zimmer J, Liu H, Liang X, Hackett S, **Campochiaro PA** (2004). Deficiency of neuropilin 2 suppresses VEGF-induced retinal neovascularization. *Mol Med* 10:12-8.
182. Liu H, Demetriades AM, Xiao WH, **Campochiaro PA**, Vinore S (2004). Mouse model of post-surgical breakdown of the blood-retinal barrier. *Curr Eye Res* 28:421-426.
183. Nambu H, Umeda N, Kachi S, Oshima Y, Akiyama H, Nambu R, **Campochiaro PA** (2005). Angiopoietin 1 prevents retinal detachment in an aggressive model of

- proliferative retinopathy, but has no effect on established neovascularization. *J Cell Physiol* 204:225-237.
184. Shen J, XiaoRu Y, Dong A, Petters RM, Peng Y-W, Wong F, **Campochiaro PA** (2005). Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. *J Cell Physiol* 203:457-464.
185. Kachi S, Oshima Y, Esumi N, Kachi M, Rogers B, Zack DJ, **Campochiaro PA** (2005). Nonviral ocular gene transfer. *Gene Ther* 12:843-851.
186. Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N, Shen J, Dong A, Apte RS, Duh E, Hackett SF, Okoye G, Ishibashi K, Handa J, Melia M, Wiegand S, Yancopoulos G, Zack DJ, **Campochiaro PA** (2005). Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive. *FASEB J* 19:963-965.
187. Saishin Y, Lima Silva R, Saishin Y, Kachi S, Aslam S, Gong YY, Hackett SF, Lai H, Carrion M, Harris B, Hamilton M, Wei L, **Campochiaro PA** (2005). Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. *Hum Gene Ther* 16:473-478.
188. Lima e Silva R, Saishin Y, Saishin Yu, Akiyama H, Kachi S, Aslam S, Rogers B, Deering T, Gong YY, Hackett SF, Lai H, Frydman BJ, Valasinas A, Marton, LJ, **Campochiaro PA** (2005). Suppression and regression of choroidal neovascularization by polyamine analogues. *Invest Ophthalmol Vis Sci* 46: 3323-3330.
189. Akiyama H, Mohamedali KA, Lima e Silva R, Kachi S, Shen J, Hatara C, Umeda N, Hackett SF, Aslam S, Krause M, Lai H, Rosenblum MG, **Campochiaro PA** (2005). Vascular targeting of ocular neovascularization with a vascular endothelial growth factor₁₂₁/gelonin chimeric protein. *Mol Pharmacol* 68: 1543-1550.
190. Nguyen QD, Shah S, Tatlipinar S, Do DV, Van Anden E, **Campochiaro PA** (2005). Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. *Br J Ophthalmol* 89: 1368-1370.
191. **Campochiaro PA** (2005). Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. *Gene Ther* 13:559-562.
192. Shen J, Samul R, Lima e Silva R, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Bargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiaro PA (2005). Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. *Gene Ther* 13:225-234.
193. Lu L, Hackett SF, Mincey A, Lai H, **Campochiaro PA** (2006). Effects of different types of oxidative stress in RPE cells. *J Cell Physiol* 206:119-125.

194. Vinores SA, Xiao Wh, Aslam S, Shen J, Oshima Y, Nambu H, Liu H, Carmeliet P, **Campochiaro PA** (2006). Implication of the hypoxia response element of the vegf promoter in mouse models of retina and choroidal neovascularization, but not retinal vascular development. *J Cell Physiol* 206: 749-758.
195. **Campochiaro PA**, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J, DiBartolomeo R, Wei LL (2006). Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. *Hum Gene Ther* 17:167-176.
196. Shen J, Yang X, Xiao WH, Hackett SF, Sato Y, **Campochiaro PA** (2006). Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. *FASEB J* 20:723-725.
197. Akiyama H, Kachi S, Lima e Silva, R, Umeda N, Hackett SF, McCauley D, McCauley T, Zoltoski A, Epstein DM, **Campochiaro PA** (2006). Intraocular injection of an aptamer that binds PDGF-B; a potential treatment for proliferative retinopathies. *J Cell Physiol* 207:407-412.
198. Kachi S, Esumi N, Zack DJ, **Campochiaro PA** (2006). Sustained expression after nonviral ocular gene transfer using mammalian promoters. *Gene Ther.* 13:798-804.
199. Cingolani C, Rogers B, Lu L, Kachi S, Shen J, **Campochiaro PA** (2006). Retinal degeneration from oxidative damage. *Free Radic Biol Med.* 40:660-669.
200. **Campochiaro PA** and the first ARVO/Pfizer Institute Working Group (2006). Ocular versus extraocular neovascularization; mirror images or vague resemblances. *Invest Ophthalmol Vis Sci.* 47:462-474.
201. Lima e Silva R, Kachi S, Akiyama H, Shen J, Aslam S, Yuan Gong Y, Khu NH, Hataru MC, Boutaud A, Peterson R, **Campochiaro PA** (2006). Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis. *J Cell Physiol.* 208:161-166.
202. Umeda N, Kachi S, Akiyama H, Zahn G, Vossmeier D, Stragies R, **Campochiaro PA** (2006). Suppression and regression of choroidal neovascularization by systemic administration of an $\alpha 5\beta 1$ integrin antagonist. *Mol Pharmacol.* 69:1820-1828.
203. Chowers I, Wong R, Dentiche T, Farkas RH, Iacovelli J, Gunatilaka TL, Medeiros NE, Presley JB, **Campochiaro PA**, Curcio CA, Dunaief JL, Zack DJ (2006). The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. *Invest Ophthalmol Vis Sci.* 47:2135-2140.
204. Dong A, Shen J, Krause M, Akiyama H, Hackett SF, Lai H, **Campochiaro PA** (2006). Superoxide dismutase 1 protects retinal cells from oxidative damage. *J Cell Physiol*

208:516-526.

205. Komeima K, Rogers B, Lu L, **Campochiaro PA** (2006). Antioxidants reduce cone cell death in a model of retinitis pigmentosa. *Proc Natl Acad Sci USA* 103:11300-11305.
206. Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, **Campochiaro PA** and the CLEAR 0305 Study Group (2006). A Phase 1 trial of intravenously administered vascular endothelial growth factor (VEGF) Trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. *Ophthalmology* 113:1522.e1-1522.e14.
207. Lochrie MA, Tatsuno GP, Arbetman AE, Jones K, Pater C, Smith PH, McDonnell JW, Zhou SZ, Kachi S, Kachi M, **Campochiaro PA**, Pierce GF, Colosi P (2006). Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5. *Virology* 353:68-82.
208. Lima e Silva R, Kachi S, Akiyama H, Shen J, Hatara MC, Aslam S, Gong YY, Khu NH, Lauer TW, Hackett SF, Marton LJ, **Campochiaro PA** (2006). Trans-scleral delivery of polyamine analogs for ocular neovascularization. *Exp Eye Res* 83:1260-1267.
209. Wu Z, Rogers B, Kachi S, Hackett SF, Sick A, **Campochiaro PA** (2006). Reduction of p66Shc suppresses oxidative damage in retinal pigmented epithelial cells and retina. *J Cell Physiol* 209:996-1005.
210. Shah SM, Tatlipinar S, Quinlan E, Tabandeh H, Nguyen QD, Fahmy AZ, Zimmer-Galler I, Symons RCA, Cedarbaum JM, **Campochiaro PA** (2006). Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography. *Invest Ophthalmol Vis Sci* 47: 5460-5468.
211. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, **Campochiaro PA** (2006). Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. *Amer J Ophthalmol* 142:961-969.
212. Pontes de Carvalho RA, Krause ML, Murphree AL, Schmitt EE, **Campochiaro PA**, Maumenee IH (2006). Delivery from episcleral explants. *Invest Ophthalmol Vis Sci* 47:4532-4539.
213. Rogers BS, Symons RCA, Komeima K, Shen J, Xiao W, Swaim ME, Gong YY, Kachi S, **Campochiaro PA** (2007). Differential sensitivity of cones to iron-mediated oxidative damage. *Invest Ophthalmol Vis Sci* 48:438-445.
214. **Campochiaro PA** (2007). Molecular targets for retinal vascular diseases. *J Cell Physiol* 210: 575-581.
215. Esumi N, Kachi S, **Campochiaro PA**, Zack DJ (2007). VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family.

- J Biol Chem 282:1838-1850.
216. Vinores SA, Xiao WH, Shen J, **Campochiaro PA** (2007) TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. *J Neuroimmunol* 182:73-79.
 217. MacGabhann F, Demetriades AM, Deering T, Packer JD, Shah SM, Duh, E, **Campochiaro PA**, Popel AS (2007) Protein transport to choroid and retina following periocular injection: theoretical and experimental study. *Ann Biomed Eng* 35:615-630.
 218. **Campochiaro PA** (2007). Gene therapy for ocular neovascularization. *Curr Gene Ther* 7:25-31.
 219. Komeima K, Rogers B, **Campochiaro PA** (2007). Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. *J Cell Physiol* 213:809-815.
 220. Yokoi K, Kachi S, Zhang HS, Gregory PD, Spratt HK, Samulski RJ, **Campochiaro PA** (2007). Ocular gene transfer with self-complementary AAV vectors. *Invest Ophthalmol Vis Sci* 48: 3324-3328.
 221. Lima e Silva R, Shen J, Hackett S, Kachi S, Akiyama H, Kiuchi K, Yokoi K, Hatara, MC, Lauer T, Aslam S, Gong YY, Xiao, W-H, Khu NH, Thut C, **Campochiaro PA** (2007). The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. *FASEB J* 21:3219-3230.
 222. Wu Z, Lauer TW, Sick A, Hackett SF, **Campochiaro PA** (2007). Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. *J Biol Chem* 284:22414-22425.
 223. Tatlipinar S, Shah SM, **Campochiaro PA**, Nguyen QD (2007). Intraobserver repeatability of automated versus adjusted optical coherence tomography measurements in patients with neovascular age-related macular degeneration. *Ophthalmologica* 221: 227-232.
 224. Do DV, Cho M, Nguyen QD, Shah SM, Handa JT, **Campochiaro PA**, Zimmer-Galler I, Sung JU, Haller JA (2007). Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. *Retina* 27: 552-556.
 225. **Campochiaro PA** (2007). Seeing the light: New insights into the molecular pathogenesis of retinal diseases. *J Cell Physiol* 213:348-354.
 226. Shen J, Xie B, Dong A, Swaim M, Hackett SF, **Campochiaro PA** (2007). In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. *Invest Ophthalmol Vis Sci*, 48:4335-4341.

227. Ghazi NG, Ciralsky JB, Shah SM, **Campochiaro PA**, Haller JA (2007). Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interface. *Am J Ophthalmol* 144:747-754.
228. Shen J, Xie B, Hatara C, Hackett SF, **Campochiaro PA** (2007). Vegf or EphA2 antisense polyamide-nucleic acids; vascular localization and suppression of retinal neovascularization. *Mol Ther* 15:1924-1930.
229. Yokoi K, Zhang S, Kachi S, Ballagan KS, Yu Q, Guschin D, Kunis M, Surosky R, Africa LM, Bainbridge JW, Spratt SK, Gregory PD, Ali RR, **Campochiaro PA** (2007). Gene transfer of an engineered zinc finger protein enhances the anti-angiogenic defense system. *Mol Ther* 15:1917-1923.
230. Shen J, Dong A, Hackett SF, Bell WR, Green WR, **Campochiaro PA** (2007). Oxidative damage in age-related macular degeneration. *Histol Histopathol* 22:1301-1308.
231. **Campochiaro PA** (2007). Targeted pharmacotherapy of retinal diseases with ranibizumab. *Drugs Today (Barc)* 43:529-537.
232. Dong A, Shen J, Krause M, Hackett SF, **Campochiaro PA** (2007). Increased expression of glial cell line-derived neurotrophic factor protects against oxidative damage-induced retinal degeneration. *J Neurochem* 103:1041-1052.
233. Nguyen QD, Shah SM, Hafiz G, Do DV, Haller JA, Zimmer-Galler I, Janjua K, Symons RC, **Campochiaro PA** (2008). Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. *Am J Ophthalmol* 145:257-266.
234. **Campochiaro PA**, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JY, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR (2008). Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. *Mol Ther* 16:791-799.
235. Doukas J, Mahesh S, Umeda N, Kachi S, Akiyama H, Yokoi K, Cao J, Chen Z, Dellamary L, Tam B, Racanelli-Layton A, Hood J, Martin M, Noronha G, Soll R, **Campochiaro PA** (2008). Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. *J Cell Physiol* 216:29-37.
236. Palanki MS, Akiyama H, **Campochiaro PA**, Cao J, Chow CP, Dellamary L, Doukas J, Fine R, Gritzen C, Hood JD, Hu S, Kachi S, Knag X, Klebansky B, Kousba A, Lohse D, Mak CC, Martin M, McPherson A, Pathak VP, Renick J, Soll R, Umeda N, Yee S, Yokoi K, Zeng B, Zhu H, Noronha G (2008). Development of prodrug 4-chloro-3-(5-methyl-3-[[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino]-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801)A a topical administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. *J Med Chem* 51:1546-1559.

237. Demetriades AM, Deering T, Liu H, Lu L, Gehlbach P, Packer JD, MacGabhann F, Popel, AS, Wei LL, **Campochiaro PA** (2008). Trans-scleral delivery of antiangiogenic proteins. *J Ocul Pharmacol* 24:70-79.
238. Xie B, Shen J, Dong A, Swaim M, Hackett SF, Wyder L, Worpenberg S, Barbieri S, **Campochiaro PA** (2008). An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization. *FASEB J* 22:2275-2283.
239. Kiuchi K, Matsuoka M, Wu JC, Lima e Silva R, Kengatharan M, Verghese M, Ueno S, Yokoi K, Khu NH, Cooke JP, **Campochiaro PA** (2008). Mecamylamine suppresses basal and stimulated nicotine-stimulated choroidal neovascularization. *Invest Ophthalmol Vis Sci* 49:1705-1711.
240. Shen J, Yang X, Xie B, Chen Y, Swaim M, Hackett SF, **Campochiaro PA** (2008). MicroRNA regulate ocular neovascularization. *Mol Ther* 16: 1208-1216.
241. Ueno S, Pease ME, Wersinger DM, Masuda T, Viores SA, Licht T, Zack DJ, Quigley H, Keshet E, **Campochiaro PA** (2008). Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons. *J Cell Physiol* 217: 13-22.
242. Komeima K, Usui S, Shen J, Rogers BS, **Campochiaro PA** (2008). Blockade of neuronal nitric oxide synthase reduces cone cell death in a model of retinitis pigmentosa. *Free Radic Biol Med* 45:905-912.
243. Yang Z, Constantine R, Francis PJ, Kleinman ME, Tan PL, Stratton C, Gibbs D, Tong Z, Chen H, Yang X, Davey L, Wang C, Walkins S, Zeng J, Harmon J, Beuhler J, Schwager A, Pearson E, Patel S, Hau VS, Kaminoh Y, Chen Y, Yu B, Zabriskie NA, Bernstein PS, Cho W, Ph.D., Hinton DR, Klein ML, Hamon SC, Simmons E, Sunness JS, **Campochiaro PA**, Genetics of AMD Study Group, Jorde L, Parmigiani G, Zack DJ, Katsanis N, Ambati J, Zhang K (2008). A common TLR3 variant confers protection from geographic atrophy in age-related macular degeneration. *N Engl J Med* 359:1456-63.
244. Lu L, Oveson BC, Jo YJ, Lauer T, Usui S, Komeima K, Xie B, **Campochiaro PA** (2009). Increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage. *Antioxid Redox Signal* 11:715-724.
245. Kachi S, Binley K, Yokoi K, Umeda N, Akiyama H, Igbal S, Kan O, Naylor S, **Campochiaro PA** (2009). EIAV vector-mediated co-delivery of endostatin and angiostatin driven by the RPE-specific VMD2 promoter inhibits choroidal neovascularization. *Hum Gene Ther* 20:31-39.
246. Do DV, Nguyen QN, Shah SM, Browning DJ, Haller JA, Chu K, Yang K, Cedarbaum JM, Vitti RL, Ingerman A, **Campochiaro PA** (2009). An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. *Br J Ophthalmol* 93:

- 144-149.
247. Esumi N, Kachi S, Hackler L Jr., Masuda T, Yang Z, **Campochiaro PA**, Zack DJ (2009). BEST1 expression in the retinal pigment epithelium is modulated by OTX family members. *Hum Mol Genet* 18: 128-141.
248. Xie B, Shen J, Dong A, Rashid A, Stoller G, **Campochiaro PA** (2009). Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. *J Cell Physiol* 218: 192-198.
249. Dong A, Xie B, Shen J, Yoshida T, Yokoi K, Hackett SF, **Campochiaro PA** (2009). Oxidative stress promotes ocular neovascularization. *J Cell Physiol* 219:544-552.
250. Takahashi K, Saishin Y, Saishin Yo, King A, Levin A, **Campochiaro PA** (2009). The multi-targeted kinase inhibitor pazopanib causes suppression and regression of choroidal neovascularization. *Arch Ophthalmol* 127:494-499.
251. Usui S, Komeima K, Lee SY, Jo Y-J, Ueno S, Rogers BS, Wu Z, Shen J, Lu L, Oveson BC, Rabinovitch PS, **Campochiaro PA** (2009). Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. *Mol Ther* 17:778-786.
252. Guaiquil V, Swendeman S, Yoshida T, Chavala S, **Campochiaro PA**, Blobel CP (2009). ADAM9 is involved in pathological retinal neovascularization. *Mol Cell Biol* 29:2694-2703.
253. Usui S, Oveson BC, Lee SY, Jo YJ, Yoshida T, Miki A, Miki K, Iwase T, Lu L, **Campochiaro PA** (2009). NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. *J Neurochem* 110:1028-1037.
254. Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS, Haller J, Do DV, Mieler WF, Chu K, Yang K, Ingerman A, Vitti RL, Berliner AJ, Cedarbaum JM, **Campochiaro PA** (2009). A phase I study of intravitreal Vascular Endothelial Growth Factor Trap-Eye in patients with neovascular age-related macular degeneration. *Ophthalmology* 116:2141-2148.
255. **Campochiaro PA**, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R, Arron JR (2009). Monitoring ocular drug therapy by analysis of aqueous samples. *Ophthalmology* 116:2158-2164.
256. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, **Campochiaro PA**; READ-2 Study Group (2009). Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. *Ophthalmology* 116:2164-2175.
257. Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, **Campochiaro PA** (2009). Effects

- of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. *Ophthalmology* 116:1748-1754.
258. Yoshida T, Zhang H, Iwase I, Shen J, Semenza GL, **Campochiaro PA** (2010). Digoxin inhibits retinal ischemia-induced HIF-1 α expression and ocular neovascularization. *FASEB J* 24:1759-1767.
259. **Campochiaro PA**, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F, for the Famous Study Group (2010). Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. *Ophthalmology* 117:1393-1399.
260. **Campochiaro PA**, Shah SM, Hafiz G, Heier JS, Lit ES, Zimmer-Galler I, Channa R, Nguyen QD, Syed B, Do DV, Lu LI, Monk J, Cooke JP, Kengatharan MK, Hsu HH (2010). Topical mecamylamine for diabetic macular edema. *Amer J Ophthalmol* 149:839-851.
261. Yang Z, Tong Z, Chen Y, Zeng J, Lu F, Sun X, Zhao C, Wang K, Davey L, Chen H, London N, Muramatsu D, Salasar F, Carmona R, Kasuga D, Wang X, Bedell M, Dixie M, Zhao P, Yang R, Gibbs D, Liu X, Li Y, Li C, Li Y, Campochiaro B, Constantine R, Zack DJ, **Campochiaro P**, Fu Y, Li DY, Katsanis N, Zhang K. (2010). Genetic and functional dissection of HTRA1 and LOC387715 in age-related macular degeneration. *PLoS Genetics* 6:e1000836
262. Miki A, Ueno S, Wesinger DM, Berlinicke C, Shaw, GC, Usui S, Wang Y, Zack DJ, **Campochiaro PA** (2010). Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. *J Cell Physiol* 224:262-272.
263. Neale BM, Fagerness J, Neale BM, Fagerness J, Reynolds R, Sobrin L, Parker M, Raychaudhuri S, Tan PL, Oh EC, Merriam JE, Souied E, Bernstein PS, Li B, Frederick JM, Zhang K, Brantley MA Jr, Lee AY, Zack DJ, Campochiaro B, **Campochiaro P**, Ripke S, Smith RT, Barile GR, Katsanis N, Allikmets R, Daly MJ, Seddon JM (2010). Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). *Proc Natl Acad Sci USA* 107:7395-7400.
264. Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J, Tosakulwong N, Pericak-Vance MA, **Campochiaro PA**, Klein ML, Tan PL, Conley YP, Kanda A, Kopplin L, Li Y, Augustaitis KJ, Karoukis AJ, Scott WK, Agarwal A, Kovach JL, Schwartz SG, Postel EA, Brooks M, Baratz KH, Brown WL; Complications of Age-Related Macular Degeneration Prevention Trial Research Group, Brucker AJ, Orlin A, Brown G, Ho A, Regillo C, Donoso L, Tian L, Kaderli B, Hadley D, Hagstrom SA, Peachey NS, Klein R, Klein BE, Gotoh N, Yamashiro K, Ferris Iii F, Fagerness JA, Reynolds R, Farrer LA, Kim IK, Miller JW, Cortón M, Carracedo A, Sanchez-Salorio M, Pugh EW, Doheny KF, Brion M, Deangelis MM, Weeks DE, Zack DJ, Chew EY, Heckenlively JR, Yoshimura N, Iyengar SK, Francis PJ, Katsanis N, Seddon JM, Haines JL, Gorin MB, Abecasis GR, Swaroop A (2010). Genetic variants near TIMP3 and high-

- density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. *Proc Natl Acad Sci USA* 107: 7401-7406.
265. Brown DM, **Campochiaro PA**, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY: CRUISE Investigators (2010). Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary endpoint results of a phase III study (2010). *Ophthalmology* 117:1124-1133.
266. **Campochiaro PA**, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators (2010). Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary end point results of a phase III study. *Ophthalmology* 117:1102-1112.
267. Silva RL, Shen J, Gong YY, Seidel CP, Hackett SF, Kesavan K, Jacoby DB, **Campochiaro PA**. (2010) Agents that bind annexin A2 suppress ocular neovascularization. *J. Cell. Physiol.* 225:855-864.
268. **Campochiaro PA**, Hafiz G, Channa R, Shah SM, Nguyen QD, Ying H, Do DV, Zimmer-Galler I, Solomon SD, Sung JU, Syed B. (2010). Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two year outcomes. *Ophthalmology* 117:2387-2394
269. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Elliott D, **Campochiaro PA** for the READ-2 Study Group (2010). Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. *Ophthalmology* 117:2146-2151.
270. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, Csaky KG, Olsen TW, Kompella UB, Holers VM, Hageman GS, Gilger BC, **Campochiaro PA**, Whitcup SM, Wong WT (2010). Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. *Invest Ophthalmol Vis Sci* 51:5403-5420.
271. Oveson BC, Iwase T, Hackett SF, Lee SY, Usui S, Sedlak TW, Snyder SH, **Campochiaro PA**, Sung JU (2011) Constituents of bile, bilirubin and TUDCA, protect against oxidative stress-induced retinal degeneration. *J Neurochem* 116:144-153.
272. Lee SY, Usui S, Zafar AB, Oveson BC, Jo YJ, Lu L, Masoudi S, **Campochiaro PA** (2011). N-acetylcysteine promotes long term survival of cones in a model of retinitis pigmentosa. *J Cell Physiol* 226:1843-1849.
273. **Campochiaro PA** (2011). Gene transfer for neovascular age-related macular degeneration. *Hum Gene Ther* 22:523-529.

274. **Campochiaro PA**, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE, for the FAME Study Group (2011). Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. *Ophthalmology* 118:626-635.
275. Channa R, Smith M, **Campochiaro PA** (2011). Treatment of macular edema due to retinal vein occlusion. *Clin Ophthalmol* 5:705-713.
276. Yu Y, Bhangale TR, Fagerness J, Ripke S, Thorleifsson G, Tan PL, Souied EH, Richardson AJ, Merriam JE, Buitendijk GH, Reynolds R, Raychaudhuri S, Chin KA, Sobrin L, Evangelou E, Lee PH, Lee AY, Leveziel N, Zack DJ, Campochiaro B, **Campochiaro P**, Smith RT, Barile GR, Guymer RH, Hogg R, Chakravarthy U, Robman LD, Gustafsson O, Sigurdsson H, Ortmann W, Behrens TW, Stefansson K, Uitterlinden AG, van Duijn CM, Vingerling JR, Klaver CC, Allikmets R, Brantley MA Jr, Baird PN, Katsanis N, Thorsteinsdottir U, Ioannidis JP, Daly MJ, Graham RR, Seddon JM (2011). Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. *Hum Mol Genet* 20:3699-3709.
277. Brown DM, **Campochiaro PA**, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY. (2011) Sustained benefits from ranibizumab for macular edema due to branch retinal vein occlusions; 12-month outcomes of a phase III study. *Ophthalmology* 118:1594-1602.
288. Usui S, Oveson BC, Iwase T, Lu L, Lee SY, Jo YJ, Wu Z, Choi EY, Samulski RJ, **Campochiaro PA** (2011). Overexpression of SOD in retina: need for increase in H₂O₂-detoxifying enzyme in same cellular compartment. *Free Radic Biol Med* 51:1347-1354.
289. Dong A, Shen J, Zeng M, **Campochiaro PA** (2011). Vascular cell-adhesion molecule-1 plays a central role in the proangiogenic effects of oxidative stress. *Proc Natl Acad Sci USA* 108:14614-14619.
290. **Campochiaro PA**, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011). Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. *Ophthalmology* 118:2041-2049.
291. Raychadhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripki S, Gowrisankar S, Vemuri S, Montgomery K, Yu Y, Reynolds R, Zack DJ, Campochiaro B, **Campochiaro P**, Katsanis N, Daly MJ, Seddon JM (2011). A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. *Nat Genet* 43:1232-1236.
292. **Campochiaro PA** (2012). Gene transfer for ocular neovascularization and macular edema. *Gene Ther* 19:121-126.
293. Heier JS, **Campochiaro PA**, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012). Ranibizumab for macular edema due to retinal vein occlusions: long term follow up in the HORIZON

- Trial. *Ophthalmology* 119:802-809.
294. de Melo J, Miki K, Rattner A, Smallwood P, Zibetti C, Hirokawa K, Monuki ES, **Campochiaro PA**, Blackshaw S (2012) Injury-independent induction of reactive gliosis in retina by loss of function of the LIM homeodomain transcription factor Lhx2. *Proc Natl Acad Sci USA* 109:4657-4662.
295. **Campochiaro PA** (2012) Anti-vascular endothelial growth factor treatment for retinal vein occlusions. *Ophthalmologica* 227 (Suppl):30-35.
296. **Campochiaro PA**, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K; FAME Study Group (2012). Sustained delivery fluocinolone acetonide vitreous Inserts provided benefit for at least 3 years in patients with diabetic macular edema. *Ophthalmology* 119:2125-2132.
297. Ohnaka M, Miki K, Gong YY, Stevens R, Iwase T, Hackett SF, **Campochiaro PA** (2012). Long term expression of glial cell line-derived neurotrophic factor slows, but does not stop retinal degeneration in a model of retinitis pigmentosa. *J Neurochem* 122:1047-1053.
298. Lu L, Seidel CP, Iwase T, Stevens RK, Gong YY, Wang X, Hackett SF, **Campochiaro PA** (2012). Suppression of GLUT1: a new strategy to prevent diabetic complications. *J Cell Physiol* 228:251-257.
299. Sobrin L, Ripke S, Yu Y, Fagerness J, Bhangale TR, Tan PL, Souied EH, Buitendijk GH, Merriam JE, Richardson AJ, Raychaudhuri S, Reynolds R, Chin KA, Lee AY, Levezuel N, Zack DJ, **Campochiaro P**, Smith RT, Barile GR, Hogg RE, Chakravarthy U, Behrens TW, Uitterlinden AG, van Duijn CM, Vingerling JR, Brantley MA Jr, Baird PN, Klaver CC, Allikmets R, Katsanis N, Graham RR, Ioannidis JP, Daly MJ, Seddon JM (2012). Heritability and Genome-Wide Association Study to Assess Genetic Differences between Advanced Age-Related Macular Degeneration Subtypes. *Ophthalmology* 119:1874-1885.
300. Nguyen QD, **Campochiaro PA**, Shah SM, Browning DJ, Hudson HL, Sonkin PL, Hariprasad SM, Kaiser PK, Slakter J, Haller JA, Do DV, Mieler W, Chu K, Ingerman A, Vitti R, Berliner AJ, Cedarbaum, and the CLEAR-IT 1 Investigators (2012). Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. *J Ocular Pharmacol Ther* 28:581-588.
301. Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, Hafiz G, **Campochiaro PA**, for the READ-2 Study Group (2013). Ranibizumab for Edema of the Macula in Diabetes Study: 3-Year Outcomes and the Need for Prolonged Frequent Treatment. *JAMA Ophthalmol* 131:139-145.
302. Iwase T, Oveson BC, Hashida N, Lima e Silva R, Shen J, Krauss AH, Gale DC, Adamson

- P, **Campochiaro PA** (2012). Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit. *Invest Ophthalmol Vis Sci* 54:503-511.
303. Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz F, Donahue JK, Rivers R, Balkissoon J, Handa JT, **Campochiaro PA**, Nguyen QD (2013). Vascular disrupting agent for neovascular age-related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. *BMC Pharmacol Toxicol* 14:7.
304. **Campochiaro PA**, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane FE (2013) Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. *Ophthalmology* 120:583-587
305. **Campochiaro PA**, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, Hepp J, Stumpp MT (2013). Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase 1/2 study. *Am J Ophthalmol* 155:697-704
306. **Campochiaro PA**, Bhisitkul RB, Shapiro H, Rubio RG (2013). Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. *Ophthalmology* 120:795-802
307. **Campochiaro PA** (2013) Ocular neovascularization. *J Mol Med (Berl)* 91:311-321
308. Bhisitkul RB, **Campochiaro PA**, Shapiro H, Rubio RG (2013). Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography. *Ophthalmology* 120:1057-1063
309. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke S, Igo RP Jr, Buitendijk GH, Sim X, Weeks DE, Guymer RH, Merriam JE, Francis PJ, Hannum G, Agarwal A, Armbrrecht AM, Audo I, Aung T, Barile GR, Benchaboune M, Bird AC, Bishop PN, Branham KE, Brooks M, Brucker AJ, Cade WH, Cain MS, **Campochiaro PA**, Chan CC, Cheng CY, Chew EY, Chin KA, Chowes I, Clayton DG, Cojocar R, Conley YP, Cornes BK, Daly MJ, Dhillon B, Edwards AO, Evangelou E, Fagerness J, Ferreyra HA, Friedman JS, Geirsdottir A, George RJ, Gieger C, Gupta N, Hagstrom SA, Harding SP, Haritoglou C, Heckenlively JR, Holz FG, Hughes G, Ioannidis JP, Ishibashi T, Joseph P, Jun G, Kamatani Y, Katsanis N, Keilhauer C, Khan JC, Kim IK, Kiyohara Y, Klein BE, Klein R, Kovach JL, Kozak I, Lee CJ, Lee KE, Lichtner P, Lotery AJ, Meitinger T, Mitchell P, Mohand-Saïd S, Moore AT, Morgan DJ, Morrison MA, Myers CE, Naj AC, Nakamura Y, Okada Y, Orlin A, Ortube MC, Othman MI, Pappas C, Park KH, Pauer GJ, Peachey NS, Poch O, Priya RR, Reynolds R, Richardson AJ, Ripp R, Rudolph G, Ryu E, Sahel JA, Schaumberg DA, Scholl HP, Schwartz SG, Scott WK, Shahid H, Sigurdsson H, Silvestri G, Sivakumaran TA, Smith RT, Sobrin L, Souied EH, Stambolian DE, Stefansson H, Sturgill-Short GM, Takahashi A, Tosakulwong N, Truitt BJ, Tsironi EE, Uitterlinden AG, van Duijn CM, Vijaya L,

- Vingerling JR, Vithana EN, Webster AR, Wichmann HE, Winkler TW, Wong TY, Wright AF, Zelenika D, Zhang M, Zhao L, Zhang K, Klein ML, Hageman GS, Lathrop GM, Stefansson K, Allikmets R, Baird PN, Gorin MB, Wang JJ, Klaver CC, Seddon JM, Pericak-Vance MA, Iyengar SK, Yates JR, Swaroop A, Weber BH, Kubo M, Deangelis MM, Léveillard T, Thorsteinsdottir U, Haines JL, Farrer LA, Heid IM, Abecasis GR; AMD Gene Consortium. Seven new loci associated with age-related macular degeneration. *Nat Genet* 45:433-439.
310. van de Ven JP, Nilsson SC, Tan PL, Buitendijk GH, Ristau T, Mohlin FC, Nabuurs SB, Schoenmaker-Koller FE, Smailhodzic D, **Campochiaro PA**, Zack DJ, Duvvari MR, Bakker B, Paun CC, Boon CJ, Uitterlinden AG, Liakopoulos S, Klevering BJ, Fauser S, Daha MR, Katsanis N, Kaver CC, Blom AM, Hoyng CV, den Hollander AI (2013). A functional variant of the CFI gene confers a high risk of age-related macular degeneration. *Nat Genet* 45:813-817.
311. Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS, **Campochiaro PA**, Green JJ (2013). Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. *Biomaterials* 34:7544-7551.
312. Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, Ying H, Do DV, Solomon S, Sodhi A, Gehlbach P, Duh E, Baranano D, **Campochiaro PA** (2013). Long-term Outcomes in Ranibizumab-Treated Patients With Retinal Vein Occlusion; The Role of Progression of Retinal Nonperfusion. *Am J Ophthalmol* 156:693-705.
312. Iwase T, Fu J, Yoshida T, Muramatsu D, Miki A, Hashida N, Lu L, Oveson B, Lima E Silva R, Seidel C, Yang M, Connelly S, Shen J, Han B, Wu M, Semenza GL, Hanes J, **Campochiaro PA** (2013). Sustained delivery of a HIF-1 antagonist for ocular neovascularization. *J Control Release* 172:625-633.
313. Dong A, Seidel C, Snell D, Ekawardhani S, Ahlskog, JKJ, Baumann M, Shen J, Iwase T, Tian J, Stevens R, Hackett SF, Stumpp MT, **Campochiaro PA** (2014). Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. *Angiogenesis* 17:553-562.
314. Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, **Campochiaro PA**; the READ-2 Study Group (2014). Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. *Eye (Lond)* 28:269-278.
315. **Campochiaro PA**, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A; RETAIN Study Group (2014). Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. *Ophthalmology* 121:209-219.
316. Valapala M, Wilson C, Hose S, Bhutto IA, Grebe R, Dong A, Greenbaum S, Gu L, Sergeev Y, Handa JT, **Campochiaro PA**, Wawrousek E, Zigler JS, Sinha D (2014). Lysosomal-

mediated waste clearance in retinal pigment epithelial cells is regulated by CRYBA1/ β A3/A1-crystallin via V-ATPase-MTORC1 signaling. *Autophagy* 10:480-496.

317. Shen J, Choy DF, Yoshida T, Iwase T, Hafiz G, Xie B, Hackett SF, Arron JR, **Campochiaro PA** (2014). Interleukin-18 has antipermeability and antiangiogenic activities in the eye: reciprocal suppression with VEGF. *J Cell Physiol* 229:974-983.
318. **Campochiaro PA**, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS (2014). Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. *Ophthalmology* 121:1783-1789.
319. Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, Kojima M, Xia H, Seidel C, Silva RL, Dong A, Hackett SF, Wang J, Howard BW, Vestweber D, Kontos CD, Peters KG, **Campochiaro PA** (2014). Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. *J Clin Invest* 124:4564-4576.
320. Zhang Y, Yao Z, Kaila N, Kuebler P, Visich J, Maia M, Tuomi L, Ehrlich JS, Rubio RG, **Campochiaro PA** (2014). Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. *Ophthalmology* 121:2432-2442.
321. Cunha-Vaz J, Ashton P, Iezzi R, **Campochiaro P**, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K, FAME Study Group (2014). Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. *Ophthalmology* 121:1783-1789
322. **Campochiaro PA**, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, Sternberg G (2014). Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. *Ophthalmology* 121:2432-2442.
323. **Campochiaro PA**, Sophie R, Tolentino M, Miller DM, Browning D, Boyer DS, Heier JS, Gambino L, Withers B, Brigell M, Peters K (2015). Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. *Ophthalmology* 122:545-554.
324. Channa R, Sophie R, Bagheri S, Shah SM, Wang J, Adeyemo O, Sodhi A, Wenick A, Ying HS, **Campochiaro PA** (2015). Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. *Am J Ophthalmol* 159:9-19.
325. **Campochiaro PA**, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Haller JA (2015). Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the Vibrant Study. *Ophthalmology* 122:538-544.
326. **Campochiaro PA**, Strauss RW, Lu L, Hafiz G, Wolfson Y, Shah SM, Mir T, Scholl HP

- (2015). Is there excess oxidative stress and damage in eyes of patients with retinitis pigmentosa? *Antioxid Redox Signal* 23:643-648.
327. Sophie R, Lu N, **Campochiaro PA** (2015). Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. *Ophthalmology* 122 (7):1395-1401.
328. **Campochiaro PA**, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Duh E, Ying H, Wenick A, Shah SM, Do DV, Nguyen QD, Kherani S, Sophie R (2015). Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: The RELATE trial. *Ophthalmology* 122 (7):1426-1437.
329. **Campochiaro PA**, Hafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian (2015). Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for retinal vein occlusion (ORVO) study. *Am J Ophthalmol* 160(2):313-321.
330. Do DV, Sepah YJ, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus DM, Halperin L, Sadiq MA, Rajagopalan N, **Campochiaro PA**, Nguyen QD (2015) Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose).*Eye (Lond)*. 29(12):1538-1544
331. **Campochiaro PA** (2015). Molecular pathogenesis of retinal and choroidal vascular diseases. *Prog Retin Eye Res* 49:67-81.
332. Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, **Campochiaro PA** (2016) Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. *Ophthalmology* 123(2):330-336.
333. **Campochiaro PA**, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K, Brigell M, TIME-2 Study Group (2016). Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. *Ophthalmology* 123:1722-1730.
334. Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, Burdon KP, Hebbaring SJ, Wen C, Gorski M, Kim IK, Cho D, Zack D, Souied E, Scholl HP, Bala E, Lee KE, Hunter DJ, Sardell RJ, Mitchell P, Merriam JE, Cipriani V, Hoffman JD, Schick T, Lechanteur YT, Guymer RH, Johnson MP, Jiang Y, Stanton CM, Buitendijk GH, Zhan X, Kwong AM, Boleda A, Brooks M, Gieser L, Ratnapriya R, Branham KE, Foerster JR, Heckenlively JR, Othman MI, Vote BJ, Liang HH, Souzeau E, McAllister IL, Isaacs T, Hall J, Lake S, Mackey DA, Constable IJ, Craig JE, Kitchner TE, Yang Z, Su Z, Luo H, Chen D, Ouyang H, Flagg K, Lin D, Mao G, Ferreyra H, Stark K, von Strachwitz CN, Wolf A, Brandl C, Rudolph G, Olden M, Morrison MA, Morgan DJ, Schu M, Ahn J, Silvestri G, Tsironi EE, Park KH, Farrer LA, Orlin A, Brucker A, Li M, Curcio CA,

- Mohand-Saïd S, Sahel JA, Audo I, Benchaboune M, Cree AJ, Rennie CA, Goverdhan SV, Grunin M, Hagbi-Levi S, **Campochiaro P**, Katsanis N, Holz FG, Blond F, Blanché H, Deleuze JF, Igo RP Jr, Truitt B, Peachey NS, Meuer SM, Myers CE, Moore EL, Klein R, Hauser MA, Postel EA, Courtenay MD, Schwartz SG, Kovach JL, Scott WK, Liew G, Tan AG, Gopinath B, Merriam JC, Smith RT, Khan JC, Shahid H, Moore AT, McGrath JA, Laux R, Brantley MA Jr, Agarwal A, Ersoy L, Caramoy A, Langmann T, Saksens NT, de Jong EK, Hoyng CB, Cain MS, Richardson AJ, Martin TM, Blangero J, Weeks DE, Dhillon B, van Duijn CM, Doheny KF, Romm J, Klaver CC, Hayward C, Gorin MB, Klein ML, Baird PN, den Hollander AI, Fauser S, Yates JR, Allikmets R, Wang JJ, Schaumberg DA, Klein BE, Hagstrom SA, Chowers I, Lotery AJ, Léveillard T, Zhang K, Brilliant MH, Hewitt AW, Swaroop A, Chew EY, Pericak-Vance MA, DeAngelis M, Stambolian D, Haines JL, Iyengar SK, Weber BH, Abecasis GR, Heid IM (2016). A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nat Gen* 48(2):134-143.
335. Mir TA, Kherani S, Hafiz G, Scott AW, Zimmer-Galler I, Wenick AS, Solomon S, Han I, Poon D, He L, Shah SM, Brady CJ, Meyerle C, Sodhi A, Linz MO, Sophie R, **Campochiaro PA** (2016) Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion. *Ophthalmology* 123(3):625-634.
336. **Campochiaro PA**, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, Wenick AS, Brady CJ, Han I, He L, Channa R, Poon D, Meyerle C, Aronow MB, Sodhi A, Handa JT, Kherani S, Han Y, Sophie R, Wang G, Qian J (2016) Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with Ozurdex Trial. *Am J Ophthalmol* 168 (8):13-23.
337. **Campochiaro PA**, Aiello LP, Rosenfeld PJ (2016) Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside. *Ophthalmology* 123 (10S):S78-S88.
338. Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, **Campochiaro PA**, Nguyen QD, Do DV, READ-3 Study Group (2016) Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes- Protocol 3 with High Dose (READ-3) Study. *Ophthalmology* 123:2581-2587.
339. Parrish RK 2nd, **Campochiaro PA**, Pearson PA, Green K, Traverso CE, FAME Study Group (2016) Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trials. *Ophthalmic Surg Lasers Imaging Retina* 47:426-435.
340. **Campochiaro PA**, Peters KG (2016) Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema. *Curr Diab Rep* 16 (12):126-137.

341. **Campochiaro PA**, Lauer AK, Sohn EH, Mir TA, Naylor S, Anderton MC, Kelleher M, Harrop R, Ellis S, Mitrophanous KA (2017) Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study. *Human Gene Ther* 28:99-111.
342. Zeng M, Shen J, Liu Y, Lu LY, Ding K, Fortmann SD, Khan M, Wang J, Hackett SF, Semenza GL, **Campochiaro PA** (2017) The HIF-1 Antagonist Acriflavine; Visualization in Retina and Suppression of Ocular Neovascularization. *J Mol Med (Berlin)* 95:417-429.
343. Lima e Silva R, Kanan, Y, Mirando AC, Kim J, Shmueli RB, Lorenc VE, Fortmann SD, Sciamanna J, Pandey NB, Green JJ, Popel AS, **Campochiaro PA** (2017) Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. *Sci Trans Med* 9(373). pii: eaai8030. doi:10.1126/scitranslmed.aai8030
344. Wykoff CC, Chakravarthy U, **Campochiaro PA**, Bailey C, Green K, Cunha-Vaz J (2017) Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. *Ophthalmology* 124:440-449.
345. Hackett SF, Seidel C, Abraham S, Chadha R, Fortmann SD, **Campochiaro PA**, Cooke JP (2017) The nicotinic cholinergic pathway contributes to retinal neovascularization in a mouse model of retinopathy of prematurity. *Invest Ophthalmol Vis Sci* 58: 1296-1303.
346. Tan PL, Garrett ME, Willer JR, **Campochiaro PA**, Campochiaro B, Zack DJ, Ashley-Koch AE, Katsanis N (2017). Systematic functional testing of rare variants: contribution of CFI to age-related macular degeneration. *Invest Ophthalmol Vis Sci* 58:1570-1576.
347. **Campochiaro PA**, Han YS, Mir TA, Kherani S, Hafiz G, Krispel C, Liu TY, Wang J, Scott AW, Zimmer-Galler I (2017) Increased frequency of topical steroids provides benefit in patients with recalcitrant postsurgical macular edema. *Am J Ophthalmol* 2178:163-175.
348. Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Celacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, **Campochiaro PA** (2017). Intravitreal injection of AAV2.sFLT01 in patients with advanced neovascular age-related macular degeneration. *Lancet* 390(10089):50-61.
349. Liu Y, Shen J, Formann SD, Wang J, Vestweber D, **Campochiaro PA** (2017). Reversible retinal vessel closure from VEGF-induced leukocyte plugging. *JCI Insight* 2(18). pii: 95530. doi: 10.1172/jci.insight.95530.
350. Chakravarthy U, Bailey C, Brown D, **Campochiaro PA**, Chittum M, Csaky K, Tufail, A,

- Yates P, Cech P, Giraudon M, Delmar P, Szczesny P, Sahni J, Boulay A, Nagel S, Furst-Recktenwald S, Schwab D (2017). Phase I trial of anti-vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. *Ophthalmology Retina* 1(6):474-485.
351. **Campochiaro PA**, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, Noronha G, for the Tanzanite Study Group (2017). Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the Tanzanite Study. *Ophthalmology Retina* 2(4):320-328.
352. Iftikhar M, Kherani S, Kaur R, Lemus M, Nefalar A, Usmani B, Junaid N, **Campochiaro PA**, Scholl HPN, Shah SM (2017). Progression of retinitis pigmentosa as measured on microrperimetry: the PREP Study. 2(5):502-507.
353. **Campochiaro PA**, Mir TA (2018). The mechanism of cone cell death in Retinitis Pigmentosa. *Prog Retin Eye Res* 62:24-37.
354. Liu Y, Fortmann SD, Shen J, Wielechowski E, Tretiakova A, Yoo S, Kozarsky K, Wang J, Wilson JM, **Campochiaro PA** (2018). AAV8-antiVEGFfab ocular gene transfer for Neovascular Age-Related Macular Degeneration. *Mol Ther* 26:542-549.
355. Kherani S, Scott AW, Wenick AS, Zimmer-Galler I, Brady CJ, Sodhi A, Meyerle C, Solomon SD, Shaikat R, Channa R, Adeyemo O, Handa JT, Wang J, **Campochiaro PA** (2018). Shortest distance from fovea to subfoveal hemorrhage border is important in patients with neovascular age-related macular degeneration. *Amer J Ophthalmol* 189:86-95
356. Fortmann SD, Lorenc VE, Shen J, Hackett SF, **Campochiaro PA** (2018). Mousetap, a novel technique to collect uncontaminated vitreous or aqueous and expand usefulness of mouse models. *Sci Rep* 8(1):6371. doi: 10.1038/s41598-018-24197-2.
357. Long D, Kanan Y, Shen J, Hackett SF, Liu Y, Hafiz Z, Khan M, Lu L, **Campochiaro PA** (2018). VEGF/VEGFR2 blockade does not cause retinal atrophy in AMD-relevant models. *JCI Insight* 3(10). pii: 120231. doi: 10.1172/jci.insight.120231.
358. Zhang Y, Bazzazi H, Lime e Silva R, Pandey NB, Green J, **Campochiaro PA**, Popel AS (2018). Three-dimensional transport model for intravitreal and suprachoroidal drug injection. *Invest Ophthalmol Vis Sci* 59(12):5266-5276.
359. Kanan Y, Khan M, Lorenc VE, Long D, Chadha R, Sciamanna J, Green K, **Campochiaro PA** (2019). Metipranolol promotes structure and function of photoreceptors in the rd10 mouse model of human retinitis pigmentosa. *J Neurochem* 148(2):307-318.
360. Mirando AC, Shen J, Lime e Silva R, Chu Z, Sass N, Lorenc VE, Green JJ, **Campochiaro PA**, Popel AS, Pandey NB (2019). A collagen IV-derived peptide disrupts $\alpha\beta1$ integrin and potentiates Ang2-Tie2 signaling. *JCI Insight*. 2019 Jan 22. pii: 122043. doi: 10.1172/jci.insight.122043

INVITED REVIEWS AND COMMENTARIES

1. Haller JA and **Campochiaro PA** (1992). Oil and gas on troubled waters: the proliferative vitreo-retinopathy studies. *Arch Ophthalmol* 110:768-769.
2. **Campochiaro PA** (1993). Cytokine production by retinal pigmented epithelial cells. *Int Rev Cytology* 146:75-82.
3. **Campochiaro PA**, Hackett SF, Vinos SA, Tobe T (1996). The retinal pigmented epithelium and retinal wound repair. *Great Basin Visual Science Symposium* 2:27-33.
4. **Campochiaro PA** (1997). Pathogenic mechanisms in proliferative vitreoretinopathy. *Arch Ophthalmol* 115:237-241.
5. **Campochiaro PA** (1997). The silicone study: A small piece of the PVR puzzle is put into place. *Arch Ophthalmol* 115:407-408.
6. **Campochiaro PA** (1999). Acute postoperative bacterial endophthalmitis. *Ophthalmology Clinics of North America* 12:83-88.
7. Kent D, Vinos SA, **Campochiaro PA** (2000). Macular edema: the role of soluble mediators. *Br J Ophthalmol* 84:542-545.
8. **Campochiaro PA** (2000). Retinal and choroidal neovascularization. *J Cell Physiol* 184:301-310.
9. **Campochiaro PA** (2002). Gene therapy for retinal and choroidal diseases. *Expert Opin Biol Ther* 2: 537-544.
10. **Campochiaro PA** (2010). The complexity of animal model generation for complex diseases. *JAMA* 303:657-658.

BOOK CHAPTERS

1. Coyle JT, Zaczek R and **Campochiaro PA** (1977). Changing Relationships among neurotransmitter systems in developing striatum: implications for neuropsychopharmacology. Proc 10th Collegium Internationale Neuro-Psychopharmacologicum, Pergamon Press, Oxford, pp. 1363-1370.
2. Coyle JT, **Campochiaro PA** and London ED (1977). Neurotoxic action of kainic acid in the developing rat striatum. Maturation of Biochemical Neurotransmission Mechanisms, Karger, Basel, pp. 134-141.
3. Coyle JT, Biziere K, **Campochiaro PA**, Schwarcz R and Zaczek R (1978). Kainic acid induced

lesion of striatum as an animal model for Huntington's Disease. GABA Neurotransmitters, Alfred Benzon Symposium 12 (H. Kofod, P. Kroggsgaard-Larsen, and J. Scheel-Kruger, eds.), Munksgaard, Copenhagen, pp 419-431.

4. Coyle JT, Biziere K, **Campochiaro PA**, London ED, Schwarcz R and Zaczek D (1979). An animal model for Huntington's Disease: striatal kainic acid lesion. Catecholamines: Basic and Clinical Frontiers, Volume 1 (E. Usdin, I. Kopin, and J. Barchas, eds.) pp 751-756.
5. **Campochiaro PA** and Blaydes SH. Localization of angiogenesis markers to inner and outer retina. Ocular Circulation and Neovascularization (D. BenEzra, S.J. Ryan, B.M. Glaser, and R.P. Murphy, eds.), Martinus Nijhoff/W. Junk, Dordrecht, pp. 401-407.
6. **Campochiaro PA**, Sen HA, Robertson TJ and Conway BP (1989). The role of breakdown of the blood-retinal barrier in proliferative vitreoretinopathy. Proliferative Vitreoretinopathy (K. Heimann and P. Wiedeman eds) Kaden, Keidelburg, pp. 45-49.
7. **Campochiaro PA**, Fogle JA and Spiker DA (1990). Management of eye-related problems due to chemical and drug toxicity. Clinical Management of Poisoning and Drug Overdose, Second Edition (L.M. Haddad and J.F. Winchester eds.), W.B. Saunders Co., Philadelphia, pp 369-388.
8. **Campochiaro PA**, Hackett SF and Viores SA (1996). Growth factors in the retina and retinal pigmented epithelium. Progress in Retinal and Eye Research (N.N. Osborne and G.J. Chader eds.), Elsevier Science Ltd, England, pp.547-567.
9. **Campochiaro PA** (1999). Diabetic retinopathy: Current treatment and prospects for pharmacologic therapy. Octreotide: The Next Decade (SWJ Lamberts ed.), BioScientifica Ltd,

LETTERS

1. Conway BP and **Campochiaro PA** (1986). Inaccuracy in preparation of intravitreal solutions. Reply. Arch Ophthalmol 104:1749.
2. **Campochiaro PA** and Conway BP (1992). Aminoglycoside toxicity. Reply. Arch Ophthalmol 110:446.
3. **Campochiaro PA** and Conway BP (1992). Aminoglycoside toxicity, a comment. Reply. Arch Ophthalmol 110:1683.
4. **Campochiaro PA** and Conway BP (1992). Intravitreal aminoglycoside toxicity revisited. Reply. Arch Ophthalmol 110:1684.
5. **Campochiaro PA** for the Aminoglycoside Study Group (1995). Aminoglycoside toxicity in the treatment of endophthalmitis. Reply. Arch Ophthalmol 113:263.
6. Nguyen QD, Shah SM, Van Anden E, Sung JU, Vitale S, **Campochiaro PA** (2004). Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 45:617-624.

7. Sophie R, Wang J, **Campochiaro PA** (2014). Re: Grunwald et al: risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials (ophthalmology 2014;121:150-161). *Ophthalmology* 121:e34.
8. **Campochiaro PA**, Hafiz G, Mir TA, Scott AW, Sophie R, Shah SM, Ying HS, Lu L, Chen C, Campbell JP, Kherani S, Zimmer-Galler I, Wenick A, Han I, Paulus Y, Sodhi A, Wang G, Qian J (2016). Reply. Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for retinal vein occlusion (ORVO) study. *Am J Ophthalmol* 161:216-217.
9. Sophie R, Lu N, **Campochiaro PA** (2016). Reply. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. *Ophthalmology* 123:e12-13.
10. **Campochiaro PA**, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Sodhi A, Duh E, Ying HS, Wenick AS, Shah SM, Do DV, Nguyen QD, Kherani S, Sophie R (2016). Reply. *Ophthalmology* 123:e33-34.
11. **Campochiaro PA**, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, Wenick AS, Brady CJ, Han I, He L, Channa R, Poon D, Meyerle C, Aronow MB, Sodhi A, Handa JT, Kherani S, Han Y, Sophie R, Wang G, Qian J (2016). Reply. *Am J Ophthalmol* 170:245-246.
12. Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, **Campochiaro PA** (2016). Reply. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT Study. *Ophthalmology* 123:e60-1.